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Hypoactive sexual desire or low libido in women are collectively referred to as 
hypoactive sexual desire disorder (HSDD).  HSDD is estimated to occur in 10% to 15% 
of adult women.  HSDD is likely the most common female sexual dysfunction (FSD) in 
menopausal women.  The hallmark of the diagnosis is personal distress and interpersonal 
difficulties resulting from low sex drive.  Most women will not seek help for this 
problem.  Studies have suggested that primary care providers and gynecologic healthcare 
providers report not feeling qualified to treat patients with sexual dysfunction, especially 
HSDD.   Testosterone, specifically transdermal testosterone, has been suggested to play 
an integral part in the treatment of HSDD in menopause.  It is proven to increase the 
frequency of satisfying sexual activity, sexual desire, and orgasmic response, and to 
decrease personal distress.  Testosterone has a demonstrated a safety history and 
medication tolerance when prescribed for this purpose.  In spite of its proven efficacy in 
relation to HSDD, the Food and Drug Administration (FDA) has not approved 
testosterone for this purpose, though its use for HSDD is currently suggested by the 
Endocrine Society in their Clinical Practice Guidelines (CPGs).  The primary purpose of 
this study was to assess Vermont primary care providers’ and gynecologic healthcare 
providers’ perceptions, knowledge, and practices regarding treatment of HSDD in 
naturally induced menopause with a focus on transdermal testosterone.  After respondent 
inclusion criteria and demographic information about the respondents was collected, the 
study asked questions and tested knowledge about topics regarding menopause and 
sexuality, evaluation of FSD, and treatment of low libido and diminished sexual desire 
with a focus on testosterone.  The study was a descriptive cross-sectional online survey 
that was completed electronically on a secure server through the University of Vermont.  
The conclusions were that providers believe sexuality and sexual satisfaction are quality 
of life indicators and perceived that maintaining sexual function is important to naturally 
occurring menopausal women.  The majority of providers would prescribe a 
pharmaceutical treatment for menopausal women seeking to maintain their sexual 
function, enhance sexual satisfaction, and/or treat symptoms of HSDD as long as there 
were no contraindications.  However, testosterone, a proven treatment for women with 
complaints of low libido and/or diminished sexual desire, was reportedly underutilized.  
This may be related to inconsistent screening for FSD in menopause at each 
comprehensive visit and lack of provider knowledge about testosterone (including safety 
and efficacy) impacting confidence to prescribe testosterone for this purpose.  Further, 
providers were divided on whether low libido and/or diminished sexual desire in 
naturally occurring menopause is a medical condition or disorder or a natural part of 
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“The literature of menopause is the saddest, the most awful, and the most medical 
of all genres. You’re sleepless, you’re anxious, you’re fat, you’re depressed - and the 
advice is always the same: take more walks, eat some kale, and drink lots of water. It 
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Chapter 1: Introduction 
Overview 
The topic of female sexual health and female sexual dysfunction (FSD) is a 
challenging one for primary care providers (PCPs) and providers of gynecologic 
healthcare.  Female sexual dysfunction is often overlooked in the primary care setting, 
even though it may be of great importance to both the patient and her sexual partner(s) 
(Wright & O'Connor, 2015; Zakhari, 2009).  The most prevalent FSD reported is 
hypoactive sexual desire and/or low libido (Leiblum, Koochaki, Rodenberg, Barton, & 
Rosen, 2006; West et al., 2008).  Hypoactive sexual desire or low libido has been 
estimated to occur in 10% to 15% of adult women in large population-representative and 
community-based studies and is likely the most common FSD in menopausal women 
(Rosen, Connor, et al., 2012).   
Hypoactive sexual desire or low libido in women is collectively referred to as 
hypoactive sexual desire disorder (HSDD) and is defined in the Diagnostic and Statistical 
Manual of Mental Disorders-5th Edition (DSM-5) and the World Health Organization’s 
(WHO) International Classifications of Disease-10 (ICD-10).  The diagnosis hinges on 
associated personal distress and interpersonal difficulties resulting from low sex drive 
and not the low drive itself (Nappi et al., 2010; Rosen, Maserejian, et al., 2012).  Most 
women will not seek help for this problem (Lindau et al., 2007; Wright & O'Connor, 
2015). 
Studies have suggested that PCPs and gynecologic healthcare providers do not 
feel qualified to treat patients with sexual dysfunction, especially HSDD (Harsh, 
McGarvey, & Clayton, 2008; Zakhari, 2009).  In part, this is thought to be related to 
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patients’ reluctance to discuss problems of HSDD with their providers.   
In menopausal women, testosterone and sexual desire are thought to be tightly 
linked because they both decline with age (Nappi, 2015a).  Therefore, testosterone, and 
specifically transdermal testosterone, has been suggested to play an integral part in the 
treatment of HSDD in menopause. It has been proven to increase the frequency of 
satisfying sexual activity, sexual desire, and orgasmic response, and to decrease personal 
distress, as well as having demonstrated safety history and medication tolerance when 
prescribed for this purpose (Davis & Braunstein, 2012; Goldstat, Briganti, Tran, Wolfe, 
& Davis, 2003; Shifren et al., 2006).   
In spite of its proven efficacy in relation to HSDD, testosterone is still not 
approved by the Food and Drug Administration (FDA) for this purpose, though its use for 
HSDD is currently suggested by the Endocrine Society in their Clinical Practice 
Guidelines (CPGs) as a treatment for HSDD (Wierman et al., 2014).  Primary care 
providers and gynecologic healthcare providers are in a position to advance sexual 
medicine for menopausal women through treatment of FSD by utilizing the CPGs in 
relation to HSDD.   
Though sexual dysfunction is common in women, particularly menopausal 
women, it remains underdiagnosed and undertreated; it may be that FSD represents a 
“silent epidemic” (Cumming, Mauelshagen, & Parrish, 2010).  Primary care providers 
and gynecologic healthcare providers are in a position to address FSD, particularly 
HSDD, with evidence-based practice that balances safety with efficacy.  In order to do 
so, the healthcare provider must be aware of their biases, perceptions, and the current 





The primary purpose of this study was to assess PCPs’ and gynecologic 
healthcare providers’ perceptions, knowledge, and practices regarding treatment of 
hypoactive sexual desire or low libido in naturally induced menopause with a focus on 
transdermal testosterone.  
Aim one.  Explore whether PCPs and gynecological healthcare providers consider 
HSDD to be a medical disorder or condition warranting pharmaceutical treatment. 
Aim two.  Evaluate provider perception of the efficacy and safety profile of 
transdermal testosterone for the treatment of low libido and diminished sexual desire in 
menopause as well as practice. 
Research Questions  
Menopause, Sexuality, and Evaluation of Female Sexual Dysfunction. Do 
primary care providers and providers of gynecologic healthcare believe sexuality and 
sexual satisfaction should be quality of life indicators for naturally occurring menopausal 
women?  Do they perceive that maintaining sexual function is important to this patient 
population?  And, do providers consistently screen naturally occurring menopausal 
women for sexual dysfunction at each comprehensive visit regardless of age, health 
status, or life circumstances?  
Low Libido and Diminished Sexual Desire in Naturally Occurring 
Menopause.  Do primary care providers and providers of gynecologic healthcare 
consider low libido and/or diminished sexual desire in naturally occurring menopausal 
women to be a medical condition or disorder, a natural part of aging, or both?  Have 
providers ever prescribed a pharmaceutical treatment for naturally occurring menopausal 
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women whose chief compliant was low libido and/or diminished sexual desire?  In their 
opinion, does the naturally occurring menopausal woman have to report feeling distressed 
and/or having interpersonal difficulties related to sexual dysfunction in order to receive 
pharmaceutical treatment for low libido or diminished sexual desire?  Furthermore, 
would they prescribe a pharmaceutical treatment for a naturally occurring menopausal 
woman who was otherwise healthy and seeking to maintain her sexual function and 
enhance sexual satisfaction as long as there are no contraindications?  
Testosterone and Hyposexual Desire Disorder.  Do primary care providers and 
providers of gynecologic healthcare feel confident in their knowledge base regarding 
testosterone used for HSDD and how does knowledge about testosterone impact practice?  
Hyposexual Desire Disorder and Clinical practice Guidelines.  Lastly, do 
providers prescribe testosterone for this purpose and have they have reviewed the 
Endocrine Society’s 2014 CPG’s regarding androgen therapy for HSDD? 
Theoretical Nursing Model Used to Guide Research 
 
The Theory of Unpleasant Symptoms (TOUS) is the nursing model used for the 
conceptual framework of this study.  TOUS was developed by four nurses: Linda Pugh 
PhD, RNC, FAAN, Elizabeth Lenz PhD, RN, FAAN, Renee Milligan PhD, RNC, 
WHNP-BC, and Audrey Gift PhD, RN and is a middle range nursing theory developed in 
1995 then updated in 1997 (Figure 1).  An excerpt from Middle Range Theory of Nursing 
proposed that this theory was developed “to improve the understanding of the symptom 
experience in various contexts and to provide information useful for designing effective 
means to prevent, ameliorate, or manage unpleasant symptoms and their negative effects” 
(McEwen & Wills, 2011, p. 236). 
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The Theory of Unpleasant Symptoms placed emphasis on the symptom 
experience with potentially other symptoms occurring concurrently, instead of looking at 
a single symptom in isolation.  The nursing implication is that successful management of 
one symptom is likely to play a positive role in other symptoms due to the commonalities 
of the symptoms (Lenz, Pugh, Milligan, Gift, & Suppe, 1997).  Lenz and colleagues 
(1997) pointed out that TOUS has three main components.  
The first component proposes that situational and/or environmental, 
psychological, and physiological factors are precursor variables or influential factors that 
have an impact on a patient’s predisposition to an unpleasant symptom experience or how 
the unpleasant symptom is manifested.  The environmental and/or situational factors are 
the components of the physical and social environment that are likely to have an impact 
on the patient’s experience resulting from the symptom.  Psychological factors include 
such components as patient’s mood and mental state (depression), the level of knowledge 
and uncertainty regarding the symptoms including their likely meanings (patient’s 
perception of the symptom experience), and the patient’s affective response to the 
symptom or illness.  Physiological factors are mostly linked to symptoms that cause 
variations in the normal body functioning such as abnormal laboratory results and 
comorbidities (Lenz et al., 1997).  
The second component is the symptom or symptoms that the patient experiences. 
The dimensions of symptoms include intensity, timing, distress, and quality.  Intensity is 
the amount, strength or severity of the symptom that the patient is experiencing.  Timing 
entails the frequency of the symptom’s occurrence, the time duration that the symptom 
persists, or a combination of both duration and frequency.  The distress component of 
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symptoms is the degree to which a patient is bothered by or reacts to the symptom(s).  
The quality component of a symptom refers to the descriptors utilized in characterizing 
the symptom.  Additionally, TOUS proposes that multiple symptoms resulting from a 
single cause can be viewed either alone or in combination (Lenz et al., 1997).  
The third component involves the outcomes associated with the symptom 
experience.  According to TOUS, performance is the outcome of symptoms and entails 
cognitive and functional activities.  Functional performance is broadly measured by 
physical activities, daily living activities, social interaction, and role performance.  
Cognitive performance entails problem solving, thinking, and concentrating.  The TOUS 
model suggests that performance depends on the nature and level of the experience 
associated with the symptom (Lenz et al., 1997).  
Figure 1. Updated version of the middle-range theory of unpleasant symptoms. 
 
Figure 1. (Lenz et al., 1997). 
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Hyposexual desire disorder in menopause may be underdiagnosed and 
undertreated in the primary care setting, in part, due to perceptions that female sexual 
complaints are thought to be too complex due to the many variables impacting sexuality.  
TOUS provides a framework for providers to link research with practice and a theory on 
which to base their management approach for naturally occurring menopausal women 
who complain of or report decreased sexual desire an/or low libido.  In essence, TOUS 
can help guide the appropriateness of a provider’s decision to prescribe testosterone for a 
patient seeking help with this problem.  
The Theory of Unpleasant Symptoms and Nurse Practitioner Competencies  
The Theory of Unpleasant Symptoms provides the framework for evidenced-
based patient centered care for HSDD as defined by the Nurse Practitioner Core 
Competencies (2014) and helps “NPs to meet the complex challenges of translating 
rapidly expanding knowledge into practice and function in a changing health care 
environment.”  Nurse practitioner competencies in conjunction with TOUS can assist 
with advancing sexual health for women in menopause through: scientific foundation (by 
critically analyzing data and evidence for improving advanced nurse practice and by 
translating research and other forms of knowledge to improve practice processes and 
outcomes), leadership (by guiding change to improve health and by providing leadership 
in the translation of new knowledge into practice), practice inquiry (by analyzing clinical 
guidelines for individualized application into practice), and independent practice 
competencies (by practicing independently and successfully managing previously 
diagnosed and undiagnosed patients through patient centered care with the patient as a 
full partner in decision making).   
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Chapter 2: Literature Review 
Background  
Female sexual complaints are common.  The 1992 National Health and Social 
Life Survey revealed that some form of sexual dysfunction affects 43% of women with 
the most common complaints being decreased desire, decreased sexual interest, and low 
libido among women of all ages, which are mediated in part by declines in testosterone 
levels and changes in sexual function following menopause (Frank, Mistretta, & Will, 
2008; Modelska & Cummings, 2003).  In 2005, The Global Study of Sexual Attitudes 
and Behaviors (GSSAB) found similar results in a larger-scaled international survey of 
sexual problems among men and women who were 40 to 80 years of age (Feldhaus-
Dahir, 2009a).  More current research indicates that only about 18% of women with 
sexual concerns spontaneously volunteer information about sexual dysfunction to their 
PCP (Wright & O'Connor, 2015).   
Low testosterone levels have been associated with loss of libido, decreased sexual 
activity, diminished feelings of physical wellbeing, and fatigue (Davis & Braunstein, 
2012; Goldstat et al., 2003; Kingsberg, 2007).  Furthermore, recent data found a 
significant positive association with testosterone, sexual desire, arousal, and masturbation 
in midlife women from the United States (US) across the menopausal transition (Nappi, 
2015a).  In a European cohort of healthy women aged 19-65 years, sexual desire was 
measured with a validated questionnaire and correlated overall with free testosterone 
(Nappi, 2015a).  Nappi (2015a) concluded that the data from the aforementioned studies 




Satisfaction with one’s sex life has been considered a major quality of life 
indicator; however, evaluation, diagnosis, and management of FSD has been largely 
overlooked by the healthcare community, especially in primary care (Krapf & Simon, 
2009; Zakhari, 2009).  This has been attributed by some to a gender gap in the 
development of sexual medicine, where the medical field has long accepted the 
importance of male sexuality but sexual dysfunction in women and treatment options to 
address these concerns have been met with controversy or a lack of acknowledgement 
(Nappi, 2015b).   
Female sexual dysfunction defined.  Historically, the DSM-4-TR divided FSD 
into four categories: sexual desire, sexual arousal, orgasmic, or sexual pain disorders 
(Frank et al., 2008).  Hence, FSD has been traditionally defined as a persistent or a 
recurrent reduction of sex drive, or an aversion to sexual activity, difficulty becoming 
aroused, an inability to reach orgasm, or pain during sexual intercourse (Frank et al., 
2008; Modelska & Cummings, 2003).  In 2004, the Second International Consensus of 
Sexual Medicine accepted revised definitions of FSD in that symptoms for sexual 
dysfunction must also cause distress (Frank et al., 2008).  In summary, to meet the 
criteria for FSD, the symptoms must be recurrent, persistent, and must also cause 
personal distress and/or interpersonal difficulty (Nappi et al., 2010; Rosen, Maserejian, et 
al., 2012). 
The DSM-5-TR diagnostic criteria combined desire and arousal disorders into 
female sexual interest/arousal disorder and sexual pain disorders into genito-pelvic 
pain/penetration disorder (Nappi, 2015b).  It also established additional criteria to 
characterize FSD, such as personal distress to diagnose female sexual interest/arousal 
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disorder (Nappi, 2015b).  Nevertheless, FSD continues to be considered a complex and 
poorly understood condition that affects women of all ages.  It is therefore considered 
difficult to diagnose and to treat (Frank et al., 2008; Modelska & Cummings, 2003; 
Nappi et al., 2010).  The body of literature regarding low libido in women continues to 
refer to the problem as HSDD, rather than female sexual interest arousal disorder.  Thus, 
HSDD will be the term used for the purpose and intent of this paper. 
Menopause and sexuality.  For myriad reasons, menopause has been associated 
with sexual dysfunction.  In part, this is thought to be related to hormonal and 
physiologic decline due to fluctuating steroid hormone levels that adversely affect the 
elasticity of the vaginal mucosa and vaginal secretions resulting in vaginal atrophy and 
pain with sexual intercourse (Thornton, Chervenak, & Neal-Perry, 2015).  Menopause is 
a time marked by social change as well.  Social conditions or life stressors, such as 
divorce, lack of partner, job loss, or declining health are thought to affect the desire for 
sexuality, however sexuality is expressed (Thornton et al., 2015). 
In an attempt to understand the prevalence of sexual activity, behaviors, and 
problems of older people, a national probability sample of 3,005 US adults 57 to 85 years 
of age comprising of 1,550 female participants were interviewed to describe the 
association between sexuality, age, and health status.  In this study, Lindau et al. (2007, p. 
3) defined sexual activity as “any mutually voluntary activity with another person that 
involves sexual contact, whether or not intercourse or orgasm occurs.”  Sexually active 
respondents were asked about the presence of sexual problems involving interest, arousal, 
orgasm, pain, and satisfaction.  Questions were also asked about the duration of the 
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sexual problem, the degree to which it occurred, and about their overall health (Lindau et 
al., 2007).   
The study by Lindau et al. (2007) showed that the prevalence of sexual activity 
declined with age (73% in the 57 to 64 years age group, 53% in the 65 to 74 years group, 
and 26% in the 75 to 85 years group were sexually active).  Women were significantly 
less likely than men to report sexual activity, and approximately half of both men and 
women reported at least one bothersome sexual problem.  The most prevalent sexual 
problem reported among older women was low desire (43%).  Yet, only 22% of the 
women in this study reported having discussed sex with a physician since the age of 50 
years (Lindau et al., 2007). 
The study by Lindau et al. (2007) was similar to the findings from the 1990 
Women’s Healthy Aging Project (WHAP) cohort, which was a prospective, longitudinal, 
epidemiological study of 438 Australian women that spanned two decades.  The study 
was also an extension of the Melbourne Women’s Midlife Health Project, where a 
significant decline from 74% to 56% in sexual activity was reported between early 
postmenopausal women and late postmenopausal women (Thornton et al., 2015).  This 
study concluded that the most important factors influencing middle-aged women’s sexual 
functioning were the previous level of sexual functioning, changes in partner status 
(gaining a new partner has a very positive effect, whereas losing a partner has a negative 
effect), feelings for a partner, and the menopausal decline in sexual functioning, which is 
related to the decline in estradiol and testosterone affecting sexual interest, arousal, 
enjoyment, orgasm, and lastly dyspareunia (Cumming et al., 2010).   
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A cross-sectional analysis of 2012/13 and a longitudinal analysis from 2002/04 of 
the population based Australian cohort of the WHAP applied validated instruments such 
as the Short Personal Experience Questionnaire (SPEQ), Female Sexual Distress Scale 
(FSDS), Hospital Anxiety and Depression Scale, and the Geriatric Depression Scale to 
describe the change in sexual functioning of women from early menopause to late 
menopause.  Two-hundred and thirty women responded, with the mean age of 70 years.  
The study concluded that in late menopause, approximately half of the women were still 
sexually active and the most important predictors were partner availability and no history 
of depression (Lonnee-Hoffmann, Dennerstein, Lehert, & Szoeke, 2014).   
Paradoxically, being sexually active or having a sexually available partner in 
menopause was associated with higher levels of personal distress (Lonnee-Hoffmann et 
al., 2014).  The authors suggested that among naturally menopausal sexually active 
women with a partner, increasing sexual distress might be related to concerns about 
declining sexual interest and activity and the effect this has on the relationship especially 




For several decades, sex has been recognized as a quality of life indicator (Nappi, 
2015b; Wylie et al., 2010; Zakhari, 2009).  Female sexual dysfunction, and in particular 
HSDD, correlates with an increased prevalence of low physical and emotional 
satisfaction, poor self-image, and unhappiness (Nappi, Wawra, & Schmitt, 2006; 
Thornton et al., 2015).  Nappi et al. (2010, p. 168) wrote, “The negative personal issues 
associated with decreased sexual interest include feeling less feminine, feeling like a 
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sexual failure, low self-esteem, insecurity, inadequacy, and letting a partner down.” 
Additionally, the distress has been positively associated with depression and it is 
particularly evident when a current partner is present (Nappi et al., 2010).   
Thornton et al. (2015) surmised that increased life expectancy for women brought 
about by improved access to medical care and nutrition have raised women’s 
expectations for a healthier longer life, and included in life quality is maintaining sexual 
function and enjoyment.  Additionally, with the FDA approval of phosphodiesterase type 
5 inhibitors for male erectile dysfunction, it has been proposed that there are now more 
menopausal women with male partners who have renewed sexual interest and improved 
function, which contributes to the prevalence of FSD and HSDD being that available 
sexual partners’ desires increase personal distress and/or interpersonal difficulty 
(Thornton et al., 2015). 
Regardless of age and menopausal status, sexual interest and the importance of 
sexuality continues for many women, regardless of declining sexual activity and function 
(Lindau et al., 2007; Thornton et al., 2015).  Seventy-six percent of 3,302 middle-aged 
multi-ethnic women in the 2003 Study of Women’s Health Across the Nation (SWAN) 
reported that sex was moderately or extremely important to them (Thornton et al., 2015).  
In an online questionnaire offered on an independent United Kingdom (UK) menopause 
website, there were 1002 female responses to a sexual questionnaire, which was patient-
tailored and clinician-led (Cumming, Herald, Moncur, Currie, & Lee, 2007).  Of the 
postmenopausal respondents, 88% reported that an active sex life was important to them 
as well (Cumming et al., 2007).   
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 Unfortunately, studies have suggested a lack of awareness of the importance of 
sex to patients on the part of PCPs, especially in older, menopausal women 
(Abdolrasulnia et al., 2010; Harsh et al., 2008).  The reluctance to enquire about sexual 
symptoms leads to an incomplete assessment of sexual function, activity, and satisfaction.  
Therefore, this reluctance has been shown to lead to a failure to legitimize the needs and 
requests of patients who desire a healthy and satisfying sex life (Abdolrasulnia et al., 
2010; Wylie et al., 2010). 
Findings from large population based studies, such as the Prevalence of Female 
Sexual Problems Associated with Distress and Determinants of Treatment Seeking 
(PRESIDE) and the Women’s International Study of Health and Sexuality (WISHeS), 
clearly indicate that FSD is a burden for many women, which poses myriad problems and 
subsequent personal distress and interpersonal difficulty (Leiblum et al., 2006; Thornton 
et al., 2015).  These studies concluded that a menopause-related decrease in sexual desire 
and low-libido can be extreme and even debilitating (Cappelletti & Wallen, 2015; 
Leiblum et al., 2006; Thornton et al., 2015).  
Hypoactive Sexual Desire Disorder in Menopause 
 
Though HSDD has been the most prevalent sexual disorder reported by women of 
all ages from multiple studies in the US and Europe, it is considered a FSD particularly 
common among menopausal women either through natural menopause or surgically 
induced menopause (Leiblum et al., 2006; Rosen, Maserejian, et al., 2012; West et al., 
2008).  The risk of HSDD is greatest in the surgically induced menopause group and is 
thought to be related to the abrupt reductions in circulating estradiol and testosterone 
levels (Thornton et al., 2015).  A US study published 2009 showed that at least 16 million 
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women over the age of 50 experience low sexual desire, with approximately four million 
meeting the criteria for HSDD (Krapf & Simon, 2009). 
Definition.  Specifically, HSDD is defined by absent/reduced interest or 
thoughts/fantasies in sexual activity, or reduced/no initiation of sexual activity, 
unreceptiveness to a partner’s initiatives, or absent/reduced sexual excitement or pleasure 
during sexuality activity that results in personal distress or interpersonal difficulty with 
no other iatrogenic or organic cause for the sexual dysfunction.  The clinical features 
must occur for at least six months (Thornton et al., 2015).  HSDD is not considered to be 
nor should be confused with an aversion to sex (Frank et al., 2008; Wright & O'Connor, 
2015). 
Generalized acquired HSDD has been the most common diagnosis when the 
condition is not dependent on a specific situation or relationship and has developed after 
a period in which sexual desire and sexual functioning were considered normal (Nappi et 
al., 2010).  The diagnosis may be comorbid with another sexual dysfunction, but it cannot 
be exclusively attributed to another medical condition or to the physiological effects of a 
medication (Nappi et al., 2010).  Hence, lack of sexual desire in menopausal women does 
not necessarily mean that they have a sexual dysfunction.  For some menopausal women, 
sexual expression ceases to become an important part of their life and is not associated 
with interpersonal distress or interpersonal difficulties and therefore, the diagnosis of 
HSDD does not apply.   
Prevalence.  Desire difficulty has been the most common FSD experienced by 
women of all ages, but particularly in either natural or surgically induced menopause.  
There have been many prevalence studies that have investigated HSDD as a FSD.   
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To determine the prevalence of HSDD among US women by reproductive status 
and age and to explore the correlates of sexually related distress, the WISHeS 
questionnaire was mailed to a national sample of US women in 2000.  The survey 
included validated questionnaires: The Short Form-36, which measured the overall health 
status; the Profile of Female Sexual Function (PFSF), which assessed sexual desire; and 
the Personal Distress (PD) Scale, which measured distress caused by low desire.  Four 
groups of women were studied: surgically postmenopausal, aged 20 to 49 years and 50 to 
70 years; premenopausal, aged 20 to 49 years; and naturally postmenopausal, aged 50 to 
70 years.  Clinically derived cutoff PFSF and PD Scale scores were used to classify 
women with HSDD and to determine its prevalence.  The relations between sexual desire 
and frequency of sexual activity or relationship satisfaction were then assessed, and the 
overall health status of HSDD women and women with normal desire were compared.  
WISHeS found that up to nine percent of natural and 26% of surgically postmenopausal 
women suffer from a persistent and distressing lack of sexual desire (Leiblum et al., 
2006).      
In another cross-sectional study of US women from 2004-2005, the prevalence of 
low sexual desire and HSDD was estimated with a focus on menopausal status.  From a 
probability sample of US households, 2207 US women aged 30 to 70 years old and in 
stable relationships were interviewed by telephone.  The analysis focused on 755 
premenopausal women, 552 naturally menopausal women, and 637 surgically 
menopausal women.  Hyposexual desire disorder was defined using the PFSF and the PD 
Scale.  Prevalence of low sexual desire ranged from 26.7% among premenopausal 
women to 52.4% among naturally menopausal women (West et al., 2008).   
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In 2004, the aforementioned study of Lindau et al. (2007) examined the 
prevalence of sexual activity, behaviors, and problems among a nationally representative 
probability sample of 3005 (1550 women and 1455 men) US citizens 57 to 85 years of 
age from households across the US.  The most prevalent sexual problem found among 
women was low desire (43%) (Lindau et al., 2007). 
Hayes et al. (2006) calculated the prevalence of sexual difficulty/dysfunction 
(desire, arousal, orgasm, and pain) using data from 11 published studies.  They found low 
sexual desire among 64% of participants (range 16–75%) orgasmic difficulties among 
35% of women (range 16–48%), arousal problems among 31% (range 12–64%) and pain 
that interfered with intercourse among 26% (range 7–28%) (Hayes, Bennett, Fairley, & 
Dennerstein, 2006; Hayes et al., 2007).  Desire was the most common sexual difficulty 
among women (Hayes et al., 2006; Hayes et al., 2007).  However, there was not 
additional data that established whether or not this caused distress (Hayes et al., 2006; 
Hayes et al., 2007).   
The first in-person diagnostic interview study published in 2012 aimed to 
determine the prevalence of generalized acquired HSDD in women aged 18 years or 
older who attended primary care clinics or obstetrics and gynecology clinics for non-
urgent visits.  In 2010 a total of 701 women were enrolled at 20 clinical sites across the 
US.  A completed two-part, self-administered questionnaire as well as a validated, 
structured, in- person diagnostic interview conducted by a trained health professional was 
used for diagnosing HSDD according to DSM-4-TR criteria.  In this sample an overall 
prevalence of acquired generalized HSDD rate was observed in 7.4% of the population 
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with a marked increase in prevalence in midlife women 40 to 59 years old (Rosen, 
Connor, et al., 2012).   
The PRESIDE survey of more than 31,000 women over 18 years of age in the US 
documented sexual distress symptoms including HSDD, which was the most commonly 
reported FSD and peaked in middle-aged women.  Between 18 to 44 years of age the 
prevalence of HSDD was 8.9%, while it was 12.3% between 45 to 64 years and 7.4 % in 
women 65 years or older (Thornton et al., 2015).  Overall, HSDD was 20% higher in 
postmenopausal than in premenopausal women (Nappi et al., 2010; Thornton et al., 
2015). 
Characteristics of menopausal women with HSDD.  A large multicenter patient 
registry was established in accordance with current guidelines to provide a 
comprehensive, longitudinal assessment of the clinical profile of women with acquired 
generalized HSDD, including both premenopausal and menopausal women receiving care 
in 33 US clinical sites and settings. Recruitment was completed in August 2010.  The 
goal of the study was to provide the first comprehensive and in-depth profile of a large, 
diverse sample of women with acquired generalized HSDD by systematically comparing 
the clinical presentation, sexual and relationship characteristics, and care seeking 
experiences.  Data was analyzed from a sample of 1,574 women enrolled in the HSDD 
Registry cohort (Rosen, Maserejian, et al., 2012).   
The results of the study demonstrated that the participants were predominately 
married or living with a partner (81.7%) and represented a range of racial and ethnic 
backgrounds. Most described their HSDD severity as “moderate to severe,” with 26.5% 
rating the problem severe.  Less than half of the overall sample had sought professional 
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help, among whom hormonal treatments had been used by only 23.7% of postmenopausal 
women and by 7.6% of the premenopausal women.  Interestingly, most women (69.8%) 
reported being happy in their relationship and 61.8% were satisfied with their partner’s 
communication (Rosen, Maserejian et al., 2012).  The conclusions of the study were that 
most of the women with HSDD were in long-term partner relationships with high levels 
of overall relationship satisfaction. 
Hyposexual desire disorder, a problematic diagnosis.  Some researchers feel 
that HSDD is a problematic diagnosis because there is no scientifically established norm 
for sexual activity, feelings, or desire (Meixel, Yanchar, & Fugh-Berman, 2015).  It has 
been suggested the HSDD is a typical example of a condition that was sponsored by the 
pharmaceutical industry to prepare the market for a specific treatment such as with 
transdermal testosterone and Flibanserin (Meixel et al., 2015).  This is what Tiefer (2006) 
referred to as FSD “disease mongering.”  Meixel et al. (2015, p.  859) asserted that 
HSDD may be a form of “disease branding” or “condition branding” as a marketing 
technique in which a company adopts or invents a condition and then develops the so-
called disease state prior to marketing pharmacological treatments for that condition.  The 
three strategies outlined by Meixel et al. (2015) to foster the creation of a condition and 
aligning it with a product (most likely pharmaceutical) are: elevating the importance of 
an existing condition, redefining an existing condition to reduce a stigma, and developing 
a new condition to build recognition for an unmet market need. 
Meixel et al. (2015) argued that HSDD is a typical example of the medicalization 
of a natural state, adding that HSDD was established by the industry in 2004 to prepare 
the market for a testosterone patch for women.  Moynihan (2005) asserted that it was 
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Robert Wilson’s bestselling book Feminine Forever that contributed to the notion the 
menopause was a disease of hormone deficiency, to be cured with hormone replacement 
which was discovered to have done more harm than good though this was primarily 
related to unopposed estrogen administration.   
Nevertheless, sexuality is considered a key aspect of women’s physical and 
psychological health potentially throughout the entire lifespan (Sobecki, Curlin, Rasinski, 
& Lindau, 2012).  The contribution of John E.  Buster, M.D.  “Managing female sexual 
dysfunction,” emphasized HSDD as a driving disorder at the heart of all other FSDs; in 
that he hypothesized that nothing happens without sexual desire (Buster, 2013).  He 
added that successful resolution of HSDD frequently facilitates resolution of other 
disorders.  Buster (2013) argued that central to understanding HSDD is the impact of the 
aging female sexual endocrinology and its effects on both prevalence and expression 
patterns of sexuality and FSD. 
General management of HSDD.  Hyposexual desire disorder is often considered 
a sexual dysfunction that is difficult to treat due to the large number of potential causes 
and contributing factors (Abdolrasulnia et al., 2010).  Nappi et al. (2010) recommended a 
balanced approach comprising both biological and psycho-relational factors.  The North 
American Menopause Society (NAMS) recommended that PCPs ask women of midlife 
age about sexual concerns at every comprehensive visit (Shifren & Gass, 2014).  Zakhari 
(2009) emphasized that, as with any condition a complete history and physical 
examination are essential to identify the etiology of the problem reported. 
Specifically, for problems of hypoactive sexual desire and/or low libido, both 
NAMS and the American Congress of Obstetricians and Gynecologists (ACOG) have 
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established recommendations for the treatment of underlying depression and anxiety as 
well as adjustment of antidepressant medications.  Other recommendations for the 
management of HSDD include examination of the problem in relation to an adverse 
situation or chronic disease such as depression, gynecological disorders, and/or the use of 
certain medications such as antidepressants, oral contraceptives, or corticosteroids 
(American Congress of Obstetricians and Gynecologists, 2012; Frank et al., 2008; 
Shifren & Gass, 2014).  The role of long-term medical diseases, especially gynecologic 
diseases, and minor ailments, medications, and psychosocial difficulties, including prior 
physical or sexual abuse, are etiologic factors that must be scrutinized (Nappi et al., 
2010).  
Counseling and sex therapy, with a focus on identifying sexual technique, 
increasing sexual novelty, and enhancing the partner relationship and communication are 
effective interventions for many individuals and couples with sexual problems 
(Abdolrasulnia et al., 2010; Rosen, Connor, et al., 2012).  In addition, identification and 
treatment of substance abuse, as well as the underlying factors that precipitated it, often 
result in improved sexuality and overall quality of life.  At the very least, it is suggested 
that the provider must provide patient education and reassurance, and make appropriate 
referrals when indicated (Frank et al., 2008). 
Current clinical guidelines for treatment of HSDD with androgen therapy. 
The complexity of factors involved in HSDD and poor awareness that low desire 
associated with distress is considered a medical condition slowed down the development 
of drugs specifically designed for women with FSD (Nappi, 2015b).  Though various 
randomized placebo-controlled trials have demonstrated efficacy and safety, the FDA has 
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not approved hormonal pharmacotherapy for HSDD (Nappi, 2015b).  Flibanserin 
(Addyi), a 5-ht1a receptor agonist, is currently the only pharmaceutical approved by the 
FDA for low sex drive in women and was made available late in 2015. 
Though there is currently no FDA approved hormonal treatments for menopausal 
women with HSDD, transdermal testosterone is considered an effective short-term 
therapy; however, there is little evidence to support long-term use (longer than six 
months) (Wierman et al., 2014).   
In 2014, the Endocrine Society updated its 2006 CPGs regarding androgen 
therapy (testosterone and dehydroepiandrosterone) in women for treatment of HSDD 
after appointing a task force consisting of the Endocrine Society, ACOG, American 
Society for Reproductive Medicine (ASRM), European Society of Endocrinology (ESE), 
and the International Menopause Society (IMS) consisting of six experts, a 
methodologist, and a medical writer.  The guidelines were published in the 2014 CPGs 
entitled "Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical 
Practice Guideline," in the Journal of Clinical Endocrinology and Metabolism (JCEM), a 
publication of the Endocrine Society (Wierman et al., 2014).   
The Society updated its 2006 recommendations to address new research 
concerning therapy in women as well as advances in testosterone testing and 
measurement techniques.  The Task Force commissioned two systematic reviews of 
published data and considered several other existing meta-analyses and trials (Wierman 
et al., 2014).  The Grading of Recommendations, Assessment, Development, and 
Evaluation (GRADE) methodology was used; the strength of a recommendation was 
indicated by a number “1” which indicated that the recommendation was strong or by a 
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“2”, which was considered to be a weak recommendation that is suggested (Wierman et 
al., 2014).   
In regards to the 2014 CPGs, the only situation where the Endocrine Society 
suggested prescribing testosterone therapy for women was if she was diagnosed with 
HSDD.  Testosterone therapy remained contraindicated in women with breast or uterine 
cancer and cardiovascular or liver disease (Nappi et al., 2010; Wierman et al., 2014).  In 
cases of HSDD without contraindications, the CPGs suggested a three-to six-month trial 
of testosterone to see if the therapy improved sexual function, but recommended against 
testosterone therapy in “otherwise healthy women” (Wierman et al., 2014).  Hence, 
transdermal testosterone therapy for HSDD is a GRADE 2 recommendation according to 
the Endocrine Society’s CPGs. 
Though monitoring androgen levels before or during treatment had not proven to 
be useful due to the inability to measure total and free testosterone in women accurately 
and precisely using currently available assays, the Endocrine Society’s 2014 guidelines 
have suggested measuring testosterone levels at baseline and after three to six weeks of 
initial treatment to assess patient overuse (Krapf & Simon, 2009; Wierman et al., 2014).  
The 2014 CPGs suggested cessation of therapy for women who have not responded 
within six months of treatment and the point was made that there was no safety and 
efficacy data for testosterone therapy after use for 24 months (Wierman et al., 2014). 
Testosterone and HSDD  
 
Testosterone has been used for more than six decades for various female disorders 
(Cappelletti & Wallen, 2015).  Though transdermal testosterone is an effective short-term 
treatment for HSDD in women, the FDA has not approved it for this use.  Nevertheless, 
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testosterone is currently prescribed as an off-label treatment for hypoactive sexual desire 
and/or low libido and its use is currently suggested by the Endocrine Society’s 2014 
CPGs for this sexual dysfunction (Cappelletti & Wallen, 2015; Wierman et al., 2014).   
Testosterone is thought to contribute to initiation of sexual activity, receptivity, 
and permission for sexual behavior (Feldhaus-Dahir, 2009a; Hollingsworth & Berman, 
2006; Nappi et al., 2003; Wylie et al., 2010).  There is also thought that testosterone can 
modulate the clitoral and vaginal physiology by facilitating vaginal smooth muscle 
relaxation, enhancing lubrication, engorgement, and sensation in part by conversion to 
estradiol (Feldhaus-Dahir, 2009a; Hollingsworth & Berman, 2006; Sherwin & Gelfand, 
1987; Traish, Kim, Min, Munarriz, & Goldstein, 2002). 
Androgens and FSD.  Low androgen levels are associated with significant 
deterioration of libido and sexuality in menopausal women.  Many studies have 
demonstrated that sexual desire, function, and activity increase with androgen 
supplementation.  This is particularly true of testosterone, a sex steroid considered to be 
the most clinically relevant circulating androgen (Feldhaus-Dahir, 2009b; Hollingsworth 
& Berman, 2006; Randolph et al., 2015).  Therefore, the decline of androgen levels 
through natural or surgically induced menopause has led to the hypothesis that decreased 
testosterone is related to diminished desire (Krapf & Simon, 2009).   
Though low circulating levels of androgens such as testosterone are associated 
with low sexual desire, the results of numerous studies addressing this are contradictory 
and no level of a single androgen is predictive of sexual dysfunction in women (Randolph 
et al., 2015; Wylie et al., 2010).  In fact, the Endocrine Society recommends against 
making a clinical diagnosis of androgen deficiency syndrome in healthy women due to 
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the lack of a well-defined syndrome, and the lack of data correlating androgen levels with 
specific signs and symptoms (Wierman et al., 2014).  Furthermore, the link between 
androgen levels and sexual dysfunction has been muddied by the inability to measure 
total and free testosterone levels in women accurately and precisely using the current 
available assays and many women tested are already taking hormonal treatments (Krapf 
& Simon, 2009; Nappi, 2015b).  Therefore, the measurement of total testosterone or free 
testosterone to diagnose androgen deficiency in clinical practice has not been typically 
utilized (Nappi, 2015b). 
Nevertheless, recent data measuring total testosterone levels found a significant 
positive association with sexual desire, arousal, and masturbation in midlife US women 
across the menopausal transition (Nappi, 2015a).  Furthermore, in a European cohort of 
healthy women aged 19 to 65 years, sexual desire, measured with a validated 
questionnaire, correlated overall with free testosterone (Nappi, 2015a).  Nappi (2015a) 
concluded that the data from the aforementioned studies support the therapeutic use of 
testosterone for low desire and sexual dysfunction in clinical conditions in which 
androgen deficiency may be accurately diagnosed though it is not typically utilized in 
clinical practice to make the diagnosis of HSDD. 
Testosterone defined.  Testosterone, a sex steroid, is synthesized from 
cholesterol in the ovaries and the adrenal glands and from the conversion of circulating 
androgens in the peripheral tissues (Feldhaus-Dahir, 2009a; Hollingsworth & Berman, 
2006; Krapf & Simon, 2009).  Total and free testosterone levels decline with age in 
premenopausal women such that women in their 40s and 50s have half the circulating 
levels of women in their 20s, after which the levels then remain stable across the 
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menopausal transition where no further decrease is observed (Goldstat et al., 2003; 
Shifren et al., 2006).  Decreases of testosterone in women are thought to decrease 
gradually due to the aging process and declining ovarian and adrenal function (Krapf & 
Simon, 2009).   
Testosterone is the most abundant active sex steroid in women throughout the 
female lifespan and is measured in 10-fold higher units than estradiol (R. Glaser & C. 
Dimitrakakis, 2013).  Additionally, there are exponentially higher levels of proandrogens: 
dihydroepiandrosterone sulfate (DHEAS), dihydroepiandrosterone (DHEA) and 
androstenedione that supply significant amounts of testosterone to the androgen receptor 
similarly in both sexes (R. Glaser & C. Dimitrakakis, 2013). 
Testosterone, a history.  Following the isolation and synthesis of testosterone in 
1935, physicians began prescribing testosterone therapy for a wide range of medical 
conditions in both men and women (Cappelletti & Wallen, 2015).  However, androgen 
therapy has been used in women since the early 1900s (Feldhaus-Dahir, 2009b).  In 
women, testosterone was frequently administered for treatment of menstrual complaints 
and as a tumor suppressant in cases of advanced breast cancer.   
In 1974, the FDA approved testosterone for female metastatic breast cancer 
(Feldhaus-Dahir, 2009b).  Early researchers anecdotally reported that some women 
treated with high-dose testosterone therapies mentioned an unexpected increase in sexual 
desire (Cappelletti & Wallen, 2015).  These women received high doses of testosterone 
(75-350 mg/week) that produced somatic virilization, such as lowering of the voice, 
clitoral enlargement, and the growth of unwanted facial hair.  In response to these initial 
studies the amount of testosterone was decreased to 20-75 mg/week to increase sexual 
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desire in female participants.  The conclusions were that testosterone increased sexual 
desire in all the participants, but that when it was combined with estrogen it was more 
effective then when taken alone.  Of note, there are no documented placebo controls from 
this time period (Cappelletti & Wallen, 2015). 
In 1983, one of the first randomized controlled trials of exogenous estrogen in 
postmenopausal women was conducted with testosterone, which was added to an 
estrogen implant in 40 menopausal women with decreased sexual interest (Dow, Hart, & 
Forrest, 1983).  No significant differences were found between the groups.  However, in 
the first study that included a testosterone alone arm, Sherwin et al. (1985) conducted a 
prospective crossover study examining the effect of intramuscular testosterone on sexual 
function in 53 surgically menopausal women.  In this study, participants were 
randomized to testosterone alone, estrogen alone, testosterone plus estrogen, or a placebo.  
Significant improvements in libido and sexual pleasure were noted in the testosterone 
treated group (Sherwin, Gelfand, & Brender, 1985).  Davis et al. (1995) conducted a 
similar study where testosterone was added to estrogen implants.  Again women 
receiving the testosterone showed significant improvements in sexual activity, 
satisfaction, pleasure, and frequency of orgasm in comparison to the estrogen group 
(Davis, McCloud, Strauss, & Burger, 1995). 
A double-blinded trial in 1998 examined the efficacy of oral testosterone therapy 
in postmenopausal women already using estrogen therapy (Sarrel, Dobay, & Wiita, 
1998).  The women were randomized into two groups: oral esterified estrogens or 
esterified estrogens plus oral methyltestosterone.  At eight weeks, the women receiving 
testosterone therapy reported significant improvements in sexual desire and satisfaction 
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(Sarrel et al., 1998).  The largest trial incorporating oral testosterone included 218 
menopausal women receiving a baseline estrogen therapy with HSDD (Lobo, Rosen, 
Yang, Block, & Van Der Hoop, 2003).  This randomized, double blind trial had a four-
month treatment period with estrogen or estrogen combined with testosterone.  
Testosterone recipients reported increased sexual desire and interest, but no 
improvements in sexual function (Lobo et al., 2003).  Then in 2004, a Cochrane database 
systematic review reconfirmed that testosterone improved libido, sexual function, and 
sexual activity (Somboonporn, Davis, Seif, & Bell, 2005). 
Hence, while earlier studies established that oral and implantable testosterone 
therapy improved sexual desire and activity in both natural and surgically induced 
menopausal women, research for other routes of administration continued.  Transdermal 
testosterone in the form of patches and gels were discovered to have the advantage of 
avoiding first-pass hepatic metabolism.  This spawned many studies of the effects of 
transdermal testosterone on a menopausal sexual desire continued (Krapf & Simon, 
2009). 
Intrinsa.  In 2004, the FDA reviewed clinical trial data for Intrinsa, a transdermal 
testosterone patch manufactured by Proctor and Gamble for the treatment of HSDD in 
postmenopausal women.  The FDA voted in favor of Intrinsa 14 to three based on the 
effectiveness in treating women with HSDD; however, it was not approved because the 
FDA felt that the 18-month clinical trial was lacking for long-term safety data (Feldhaus-
Dahir, 2009a).   
Impact of the Women’s Health Initiative.  Feldhaus-Dahir (2009) suggested that 
medical professionals believed that the FDA was apprehensive to approve transdermal 
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testosterone due to the results of the 2002 Woman’s Health Initiative (WHI), which 
showed that treatment with estrogen and progestin caused breast cancer (Shufelt & 
Braunstein, 2009).  Since testosterone is considered to be by some a prohormone for 
estradiol, testosterone use in women raised concerns that conversions to estrogen at the 
local tissue level may be deleterious, especially with cardiovascular, breast, and 
endometrial health (Feldhaus-Dahir, 2009b).  Since then, all forms of hormone therapy in 
menopausal women have  come into question and under close scrutiny (Feldhaus-Dahir, 
2009b). 
Testosterone and antidepressant treatment-emergent loss of libido.  Female 
sexual dysfunction is a side effect of selective serotonin and noradrenalin reuptake 
inhibitor therapy (SSRI/SNRI).  A double-blind, randomized, placebo-controlled study 
was conducted on 44 women aged 35 to 55 years who were on a stable dose of SSRI or 
SNRI with treatment-emergent loss of libido.  The women were randomly allocated to 
treatment with a transdermal testosterone patch delivering 300 mcg of testosterone/day or 
an identical placebo patch for 12 weeks.  The primary outcome measure was the change 
in the Sabbatsberg Sexual Self-Rating Scale (SSS) total score over 12 weeks. The four-
week frequency of Satisfactory Sexual Events (SSEs) and the Female Sexual Distress 
Scale-Revised (FSDS-R) were also measured (Fooladi et al., 2014). 
The mean total serum testosterone level at 12 weeks in the transdermal group was 
2.1 nmol/L.  The increase in the four-week frequency of SSEs was significantly greater 
for the transdermal testosterone group than the placebo group (an increase of 2.3 events 
vs. 0.1), though the change in the SSS score did not differ between the two groups and 
the between-group difference in the change in the FSDS-R score only approached 
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statistical significance.  No women withdrew because of androgenic adverse events.  It 
was concluded that transdermal testosterone therapy resulted in a significant increase in 
the number of SSEs in comparison to the placebo therapy in women with SSRI/SNRI 
emergent loss of libido.  This study provided the first evidence that transdermal 
testosterone therapy may be a treatment option for women with SSRI/SNRI emergent 
loss of libido who need to remain on their antidepressant therapy (Fooladi et al., 2014). 
Studies that evaluate the safety and efficacy of transdermal testosterone.  
Based on presentations at a satellite symposium during the 2011 annual meeting of the 
International Society for the Study of Women’s Sexual Health, it was determined that 
transdermal testosterone is considered an effective and safe therapy for menopausal 
women with HSDD.  The safety and efficacy were demonstrated with and without 
concomitant estrogen or estrogen/progestin therapy based on randomized, double-blind, 
placebo controlled studies.  Furthermore, interim data from a long-term phase three-
safety trial of a testosterone gel has continued to demonstrate a low rate of cardiovascular 
events and breast cancer in postmenopausal women at an increased cardiovascular risk 
(Davis & Braunstein, 2012). 
Phase three trials.  To investigate the efficacy and safety of transdermal 
testosterone, two concurrent phase-three trials were conducted in the US, Canada, and 
Australia.  These two large, double-blind multicenter trials are known as the Investigation 
of Natural Testosterone in Menopausal Women Also Taking Estrogen in Surgically 
Menopausal Women (INTIMATE SM) 1 and 2 and specifically investigated the safety of 
a 300-mcg/day-testosterone patch for HSDD in surgically induced menopausal women 
who are taking transdermal or oral estrogen (Davis & Braunstein, 2012; Krapf & Simon, 
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2009; Shifren et al., 2006).  Taken together, the findings supported the efficacy of the 
300-mcg/day-testosterone patch for low sexual functioning women who report low 
stressful sexual desire after a bilateral salpingo-oophorectomy and hysterectomy and are 
using estrogen therapy (Krapf & Simon, 2009).   
Both trials were 32 weeks in duration, consisting of an eight-week pre-treatment 
baseline period and a 24-week randomized double-blind placebo controlled treatment 
period.  Patients in both trials had undergone bilateral salpingo-oophorectomy and a 
hysterectomy at least six months previously and were receiving estrogen therapy.  All 
women were in monogamous relationships with a sexually functioning partner and 
reported a meaningful loss of sexual desire that was causing them concern (Kingsberg, 
2007).  Women with sexual dysfunction such as dyspareunia or who were taking 
medications known to cause sexual dysfunction such as selective serotonin reuptake 
inhibitors were excluded from the study.  A key feature of the trials was the use of a 
validated study instruments to measure sexual function.  The primary efficacy measure 
was the change in the frequency of total satisfying sexual activity over 24 weeks assessed 
by the Sexual Activity Log (SAL), which is described as a weekly diary that assessed 
sexual activity, satisfying sexual events, and number of orgasms over the proceeding 
seven days.  Secondary efficacy measures included changes in the Profile of Female 
Sexual Function (PFSF).   Additionally, the subject’s distress related to lack of interest in 
sex was measured with the Personal Distress Scale (PDS).  Both studies concluded that 
transdermal testosterone treatment for HSDD is effective in surgically menopausal 
women taking estrogen (Kingsberg, 2007). 
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Furthermore, the INTIMATE SM 1 and 2 studies both showed a similar adverse 
event profile.  In both studies, the most commonly reported adverse events were skin 
reactions at the site, which occurred in 30-40% of the participants (Kingsberg, 2007).  
Androgenic adverse events, such as acne, alopecia, or voice deepening tended to be more 
common in testosterone treated patients than in the placebo group in INTIMATE SM 2, 
but not INTIMATE SM 1.  The androgenic adverse events were not considered to be 
significant for 85% of the participants stated that they would continue treatment.  
Due to the concerns about the safety and efficacy of testosterone without 
concurrent estrogen therapy on low sexual desire and libido in postmenopausal women, 
the phase three Research Study of Female Sexual Dysfunction in Women on Testosterone 
Patch without Estrogen (APHRODITE) study attempted to address this lack in the 
research and is so far the longest trial to date, spanning 52 weeks (Krapf & Simon, 2009). 
Though menopausal women with HSDD experienced statistically significant 
improvements in the frequency of satisfying sexual activity, sexual desire, and distress 
with testosterone treatment in phase three trials it was not known if the magnitude of the 
effects were clinically meaningful.  Therefore, a representative sample of two 
randomized placebo-controlled trials (N=1094) were interviewed before un-blinding at 
the end of the study to assess the efficacy and safety of 300 mcg/day of transdermal 
testosterone.  Women were asked, “Overall, would you say that you experienced a 
meaningful benefit from the study patches?” Fifty-two percent of the women receiving a 
testosterone patch experienced a meaningful treatment benefit in comparison to the 31% 
who received placebo.  Therefore, the conclusions were that surgically menopausal 
women with HSDD received clinically meaningful benefits (Kingsberg et al., 2007). 
 33 
 
INTIMATE NM1.  This study was the first large, multicenter, randomized, 
double-blind, placebo-controlled parallel group trial to evaluate the safety and efficacy of 
transdermal testosterone therapy among surgically induced menopausal women with 
HSDD on a stable dose of oral estrogen with or without progestin (N=549) (Shifren et al., 
2006).  Women were randomized to receive testosterone 300 mcg/day or placebo patches 
twice weekly for 24 weeks.  The primary efficacy measure was change from baseline in 
frequency of total satisfying sexual activities over a four-week period.  The results 
demonstrated that there was a change in the number of total satisfying sexual episodes for 
the participants on testosterone compared with placebo.  The results also demonstrated 
that testosterone also produced statistically significant improvements compared with 
placebo in all secondary efficacy measures, including sexual desire and personal distress.  
Furthermore, the patch was well tolerated (Shifren et al., 2006). 
INTIMATE NM2.  This study used the same instruments for assessments of FSD 
as in the INTIMATE NM1 study and the participants had surgically induced menopause.  
Five hundred and thirty-two surgically induced postmenopausal women aged 31 to 56 
years with HSDD were randomly assigned to either a 300-mcg/day-testosterone patch or 
placebo with either oral or transdermal estrogen.  Testosterone recipients reported an 
increase of 1.56 satisfying sexual episodes per four weeks versus 0.73 episodes per four 
weeks with placebo, an increase from 51% versus 23% from baseline for each group.  
Overall, sexual desire increased 49% from baseline in the testosterone group (Krapf & 
Simon, 2009).   
APHRODITE.  This phase three trial studied testosterone’s safety and efficacy in 
women not taking concurrent estrogen therapy.  The women from 65 centers in the US, 
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Canada, Sweden, and the United Kingdom participated between 2004 and 2006.  In this 
study Davis et al. (2008) conducted a double-blinded placebo controlled trial of 814 
women with HSDD who were not currently taking estrogen. The women were randomly 
assigned to a 150 mcg/day-testosterone patch, a 300 mcg/day-testosterone patch, or 
placebo patch.  The primary endpoint of frequency of satisfying sexual episode in 
addition to assessment of FSD using the SAL, PFSF, and PD scale were measured after a 
24-week trial period (Davis et al., 2008).  Safety was assessed throughout week 52 and an 
optional extension phase was continued for an additional year.   
Consistent with the results in the INTIMATE studies, there was an increase in the 
number of sexually satisfying episodes in the women receiving 300-mcg/day testosterone 
patches, but not in the 150-mcg group (Davis et al., 2008).  The 300-mcg group reported 
2.1 satisfying sexual episodes per four weeks, verses 0.7 episodes in the placebo group, 
which equates to 78% sexually satisfying experienced on the higher testosterone group 
compared to 65% for placebo (Davis et al., 2008).  The 300-mcg group also reported 
higher scores for sexual desire and decreased scores for personal distress (Krapf & 
Simon, 2009).  The rate of androgenic adverse effects, primarily unwanted hair growth, 
was higher in the group receiving 300 mcg/day of testosterone than in the placebo group 
(30% vs. 23.1%).  Breast cancer was diagnosed in four women who received 
testosterone, as compared to none who received placebo.  One of the four received the 
diagnosis in the first four months of the study period, and one in retrospect had symptoms 
before undergoing randomization.  The primary reasons for withdrawal were application 
site reactions.  Clitoral enlargement happened in four women receiving testosterone; 
however, none of these women withdrew from the study and subsequent examination 
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revealed resolution (Davis et al., 2008).  The groups did not differ significantly in respect 
to serum lipid profiles. 
ADORE.  The ADORE study sought to evaluate the efficacy and safety of a 
transdermal testosterone patch of 300 mgs/day in naturally menopausal women with 
HSDD.  A total of 272 naturally menopausal women who were predominantly not using 
hormone therapy were randomized in this six-month, placebo-controlled, double-blind, 
multicenter study to receive twice weekly of either transdermal testosterone or an 
identical placebo.  Efficacy endpoints measured were the four-week frequency of 
satisfying sexual episodes (SSE) using the Sexual Activity Log, the sexual desire domain 
of the Profile of Female Sexual Function and distress by the Personal Distress Scale. 
Safety was assessed by monitoring adverse events, laboratory parameters, and hormone 
levels (Panay et al., 2010). 
The transdermal testosterone group demonstrated significant improvements in 
SSE as well as in sexual desire and reduced personal distress versus placebo at six 
months.  Similar numbers of women treated with placebo and transdermal testosterone 
withdrew from the study due to adverse events including application site reactions. 
Serum free and total testosterone levels increased from baseline in the transdermal 
testosterone group within the physiological range.  The conclusion of the study was that 
transdermal testosterone was effective in treating HSDD and improving sexual 
dysfunction in naturally menopausal women with and without concurrent hormone 
therapy (Panay et al., 2010). 
Phase two trials.  Shifren and colleagues (2000) conducted the first randomized, 
double-blinded placebo controlled study of a transdermal testosterone patch.  Seventy-
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five surgically induced menopausal women aged 31 to 56 years with self-reported 
impaired sexual dysfunction taking estrogen therapy were randomly assigned to either a 
150 mcg/day testosterone patch, a 300 mcg/day testosterone patch, or placebo.  Women 
receiving 300 mcg/day of testosterone reported significantly higher scores for frequency 
of sexual activity, sexual fantasies, masturbation, and orgasm than those in the lower 
testosterone group (Shifren et al., 2000). 
Another phase two trial followed in 2005, which included a larger patient 
population, a longer treatment period, and a higher dosage group.  Braunstein et al. 
(2005) randomized 318 surgically induced menopausal women with HSDD who were 
already receiving oral estrogen therapy to a 24-week period of varying doses of the 
testosterone patch (150 mcg/day, 300 mcg/day, or 450 mcg/day), or a placebo.  This 
study used three validated efficacy instruments to assess FSD: The Profile of Female 
Sexual Function (PFSF), the Profile of Sexual Activity (SAL), and the Personal Distress 
Scale (PDS).  Interestingly, significant increases in sexual desire and frequency of 
satisfying sexual activity were found only in the 300-mcg group compared with placebo 
(sexual desire increased 67% from the baseline verses an increase of 48% with placebo 
and sexually satisfying experiences increased 0.58 each week).  No treatment effect was 
seen in the 150 mcg/day or in the 450 mcg/day, which raised the suspicion of a 
testosterone dose curve.  Of note, frequency of adverse events was similar among all 
groups with no severe events reported (Braunstein et al., 2005). 
Small community based trials of testosterone’s efficacy on surgically induced 
menopausal participants.  In 2007 El-Hage et al. (2007) conducted a double-blind cross 
over study that included hysterectomized postmenopausal women who were already 
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taking transdermal estrogen.  The 36 menopausal healthy women who were recruited had 
undergone a hysterectomy, were not depressed, were in a stable relationship, and filled 
the diagnostic criteria for low sexual desire, as measured by the Brief Index of Sexual 
Function for Women (BISF-W) (El-Hage, Eden, & Manga, 2007).  The researchers found 
that 10 mgs of topical cream significantly improved sexual desire, frequency of sex, 
receptivity, and initiation of sex as measured by the BISF-W (El-Hage et al., 2007; Krapf 
& Simon, 2009). 
In another study, a representative sample of 132 surgically postmenopausal 
women with HSDD was enrolled in two randomized, placebo-controlled trials (N=1094) 
that assessed the efficacy and safety of transdermal testosterone treatment (300 mcg/day) 
for 6 months.  At the end of the study, prior to un-blinding, a sample of women (12%) 
was interviewed concerning their experiences with the treatment.  The conclusions were 
that surgically menopausal women with HSDD received clinically meaningful benefits, 
including improvements in satisfying sexual activity, sexual desire, and personal distress 
(Kingsberg et al., 2007). 
Small community based trials of premenopausal women with low libido.  
Premenopausal women with low libido participated in a randomized, placebo controlled, 
crossover efficacy study of testosterone cream (10 mg/day) with two double-blind, 12-
week, treatment periods separated by a single blind, four-week washout period.  Thirty-
four women completed the study and 31 provided complete data.  Testosterone therapy 
resulted in a statistically significant improvement in the composite scores of 
Psychological General Wellbeing Index and the Sabbatsberg Sexual Self-Rating Scale 
compared with placebo.  A mean decrease in the Beck Depression Inventory score 
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approached significance.  Mean total testosterone levels during treatment were at the high 
end of normal range and estradiol was unchanged.  Conclusions were that testosterone 
therapy improved wellbeing, mood, and sexual dysfunction in premenopausal women 
(Goldstat et al., 2003).   
Cochrane reviews.  Two Cochrane reviews have recently examined the benefits 
and risks of testosterone therapy plus estrogen-progestin (EPT) versus EPT alone for 
perimenopausal and postmenopausal women by including 35 studies with 4,768 
participants.  The majority of the trials included both naturally and surgically 
postmenopausal women.  Testosterone regimens included oral tablets, intramuscular 
injections, subcutaneous implants, and transdermal patches and gels.  The median study 
duration was six months (range 1.5–24 months).  The pooled estimate from the clinical 
trials suggested that the addition of testosterone to hormone therapy regimens improved 
sexual function scores and number of total satisfying sexual episodes in postmenopausal 
women.  Beneficial effects were seen for the composite sexual function score and 
domains of sexual activity, coital frequency, responsiveness, and desire (Nappi et al., 
2010).   
Testosterone side effect and safety profile.  The findings and conclusions from 
many smaller studies are similar to the results found in a MEDLINE literature review, 
cross-reference of published data, and review of the FDA, all of which critically 
examined the safety of testosterone therapy given to menopausal women (Braunstein, 
2007).  The broad conclusions are that except for hirsutism and acne with or without 
estrogen, the administration of transdermal testosterone in physiologic doses is safe.  
However, long-term safety of testosterone as a hormone replacement therapy has not 
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been well established because the majority of prospective studies ranged from one to two 
years (Braunstein, 2007; Davis & Braunstein, 2012; Shufelt & Braunstein, 2009).  Thus, 
prospectively collected long-term studies are needed to provide a greater degree of 
assurance (Davis & Braunstein, 2012; Shufelt & Braunstein, 2009).   
Short-term safety has been demonstrated with many randomized, placebo-
controlled studies as well as the documented side effects (Davis & Braunstein, 2012).  As 
already mentioned, the most common side effects of testosterone therapy include mild 
and reversible acne and hirsutism, which has been observed in the use of testosterone 
with and without estrogen.  These side effects are thought to be dose dependent 
(Braunstein, 2007; Shufelt & Braunstein, 2009).  Virilization such as deepening of the 
voice and clitoromegaly are rare with low dose therapy and has not been at all observed 
in menopausal women treated with physiologic doses for HSDD (Braunstein, 2007; 
Davis & Braunstein, 2012).  Changes to the lipid profile such as decreasing high-density 
lipoprotein (HDL) was noted with oral, but not transdermal testosterone, which bypasses 
hepatic metabolism (Davis & Braunstein, 2012; Shufelt & Braunstein, 2009). 
The major safety concerns surrounding testosterone therapy in women are related 
to potential adverse effects on the cardiovascular system and stimulation of the 
endometrium and breast tissue leading to carcinoma.  Liver toxicity and behavioral 
effects have also been called into question (Braunstein, 2007; Davis & Braunstein, 2012).  
Short-term studies of up to two years have shown that for serum plasma testosterone 
levels at the upper portion or slightly above the reference range for reproductive aged 
women, testosterone does not increase the risk of hepatotoxicity, endometrial 
hyperplasia, or behavioral hostility.  No adverse cardiovascular effects including changes 
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in blood pressure, blood viscosity, arterial vascular reactivity, hypercoagulable states, and 
polycythemia have been shown (Shufelt & Braunstein, 2009).  The side effects and safety 
profile that have been most scrutinized are related to breast and cardiovascular health; 
however, while testosterone does not appear to adversely impact either of these 
conditions, it is thought that it may provide a protective effect (R. L. Glaser & C. 
Dimitrakakis, 2013). 
Breast cancer.  Concerns have been raised that either directly or indirectly 
androgens stimulate the development or growth of breast cancer despite of the fact that 
androgens have been used to treat breast cancer (Braunstein, 2007; Hofling et al., 2007).  
Data is mixed with outcomes of breast cancer risk with some experimental studies 
suggesting a decrease in estrogen-induced breast epithelial proliferation with low dose 
testosterone.  There are no randomized trials that show a risk between breast cancer and 
testosterone therapy, although four participants in the APHRODITE phase three trial 
developed breast cancer in the testosterone group (Davis et al., 2008; Feldhaus-Dahir, 
2009a).   
Feldhaus-Dahir (2009b) discussed the method and results of a retrospective 
observational study regarding breast cancer and hormone replacement therapy in 2004, 
which showed that among 508 postmenopausal women reviewed over a mean of 5.8 
years, the incidence of breast cancer was not different among those who used estrogen 
alone, those who combined estrogen with testosterone, or those who used no hormones at 
all.   It is now understood that postmenopausal exogenous use of estrogen is associated 
with an increase in breast cancer.  Additionally, models of super-physiologic testosterone 
levels, such as in polycystic ovarian syndrome (PCOS) or in female to male transgender 
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individuals have not shown an increased risk of breast cancer (Davis & Braunstein, 
2012).   
The first six-month prospective, randomized, double-blind, placebo-controlled 
prospective study that measured the effects of testosterone on breast cell proliferation was 
performed on 99 postmenopausal women (Hofling et al., 2007; Krapf & Simon, 2009).  
Hofling et al. (2007) gave the participants estrogen and progestin and then randomized to 
transdermal testosterone or a placebo patch.  Fine needle aspiration biopsies were taken at 
baseline and at six months to evaluate the epithelial and stromal cell proliferation.  There 
were no significant differences for the women who were randomized to testosterone, 
while there was more than a five-fold increase in breast cell proliferation in women on an 
estrogen-progestin placebo patch (Davis & Braunstein, 2012; Hofling et al., 2007).   
The effects of exogenous testosterone on breast cancer risk remain unclear.  Of 
eight observational studies in populations receiving testosterone alone or in combination 
with estrogen or estrogen/progestin, only two reported a significant increase in breast 
cancer.  Among these, a retrospective cohort study suggested an increased risk of breast 
cancer in women taking exogenous testosterone, primarily methyltestosterone, but other 
studies showed inconsistent associations.  Of note, these studies were known to have  
methodological problems, including but not limited to a small sample size and a lack of 
matches for other breast cancer risk factors (Davis & Braunstein, 2012). 
Evidence from other studies has suggested that androgens are breast protective.  
To investigate the incidence of breast cancer in women who were treated with 
subcutaneous testosterone therapy in the absence of systemic estrogen therapy, a five-
year interim analysis of a 10-year, prospective, observational study investigated the 
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incidence of breast cancer in women who presented with symptoms of hormone 
deficiency treated with subcutaneous testosterone implants or testosterone combined with 
the aromatase inhibitor (AI) anastrozole implants.  Breast cancer incidence was compared 
with that of historical controls reported in the literature, age specific Surveillance 
Epidemiology and End Results (SEER) incidence rates, and a representative, similar age 
group of patients used as a control group.  The effect of adherence to testosterone therapy 
was also evaluated (R. L. Glaser & C. Dimitrakakis, 2013). 
Since March 2008, 1,268 pre-and-post-menopausal women have been enrolled in 
the study and eligible for analysis.  As of March 2013, there have been eight cases of 
invasive breast cancer diagnosed in 5,642 person-years of follow up for an incidence of 
142 cases per 100,000 person-years, which is substantially less than the age-specific 
SEER incidence rates (293/100,000), placebo arm of Women’s Health Initiative Study 
(300/100,000), never users of hormone therapy from the Million Women Study 
(325/100000), and the control group (390/100,000).  Unlike adherence to estrogen 
therapy, it was discovered that adherence to testosterone therapy further decreased the 
incidence of breast cancer (73/100,000) (R. L. Glaser & C. Dimitrakakis, 2013). 
Furthermore, testosterone and/or testosterone and anastrozole reduced the 
incidence of breast cancer in premenopausal and postmenopausal women.  The evidence 
supported that breast cancer is preventable by maintaining a testosterone to estrogen ratio 
in favor of testosterone and, in particular, the use of continuous testosterone or when 
indicated testosterone and anastrozole.  The final summary and conclusion were that 
testosterone hormone therapy has been recommended for further investigation for the 
prevention and treatment of breast cancer (R. L. Glaser & C. Dimitrakakis, 2013). 
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Lending to the above-mentioned studies is the knowledge that women with breast 
cancer have better cancer-related outcomes with the use of AIs, but the physiological 
suppression of estradiol can negatively affect sexual functioning because of unpleasant 
urogenital and vaginal symptoms (Dahir & Travers-Gustafson, 2014).  Therefore, a pilot 
study was conducted to research the effects of vaginal testosterone therapy on sexual 
quality of life in women with breast cancer taking AI therapy. Thirteen postmenopausal 
women with breast cancer on AI therapy and experiencing symptoms of sexual 
dysfunction were recruited from an oncology practice.  The women were prescribed a 
300-μg testosterone vaginal cream daily for four weeks.  The Female Sexual Function 
Index (FSFI) survey, measuring female sexual health quality of life, was administered 
during the first study visit and at the final study visit after completing testosterone 
therapy. Twelve patients completed four weeks of daily vaginal testosterone therapy. 
When compared with baseline FSFI scores, there was a statistically significant 
improvement for individual domain scores of desire, arousal, lubrication, orgasm, 
satisfaction, and pain.  Total domain scores reflecting sexual health quality of life also 
improved when compared with baseline.  The conclusions were that the use of a 
compounded testosterone vaginal cream applied daily for four weeks improves reported 
sexual health quality of life in women with breast cancer taking AIs (Dahir & Travers-
Gustafson, 2014). 
Cardiovascular disease.  There have been no associations between endogenous 
levels of testosterone in women and coronary artery disease (CAD) and in some cases a 
protective effect had been shown (Braunstein, 2007; Davis & Braunstein, 2012; Shufelt 
& Braunstein, 2009).  Prospective studies do not support a causal role of high 
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endogenous androgen levels in cardiovascular events or deaths in older women (Davis & 
Braunstein, 2012).  In a study of 693 women with and without established CAD, age 
adjusted levels of androgens showed no statistical difference.  Androgen levels were not 
predictive of cardiovascular death in this cohort that was followed for 19 years 
(Braunstein, 2007; Shufelt & Braunstein, 2009).  In another population-based study with 
a median follow-up of 12.3 years, it was noted that the optimal range for testosterone-
promoted cardiovascular health with an increased risk for cardiovascular events at the 
upper and lower levels of bioavailable testosterone (Davis & Braunstein, 2012). 
Testosterone treatment in women at the doses used for treating HSDD has been 
found to not adversely affect the cardiovascular safety profile (Davis & Braunstein, 
2012).  Lipid alterations noted with exogenous testosterone appear to be dependent on the 
route of administration.  Because of the first pass effect, changes in the lipid profile and 
particularly a reduction in the HDL cholesterol are observed with oral testosterone given 
concomitantly with estrogens, whereas transdermal testosterone administered with 
estrogen has been shown to be lipid-level neutral.  In a two-year study on clotting factors, 
no differences in levels of fibrinogen, thrombotic, or fibrinolytic proteins were observed 
in women who were receiving testosterone subcutaneous implants (Davis & Braunstein, 
2012).  Polycythemia has not been reported in women receiving physiologic doses of 
testosterone and the large doses of testosterone used to treat female-to-male transgender 
subjects increase hemoglobin only to the level found in normal healthy men (Davis & 
Braunstein, 2012).   
While women with PCOS have hyperandrogenemia as well as an increased risk of 
CAD, the mechanism is believed to be secondary to hyperinsulinemia related to visceral 
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obesity, insulin resistance, and dyslipidemia.  Adding to this, studies show that 
physiologic doses of testosterone either oral or transdermal does not lead to insulin 
resistance or a change in fasting glucose.  Additionally, the authors reported no 
cardiovascular mortality over 2,418 patient-years of treatment in 293 female-to-male 
transsexuals who received male testosterone replacement doses from two months to 41 
years.  There was only one case of a myocardial infarction and angina and 12 patients had 
increased blood pressure (Davis & Braunstein, 2012).   
Endometrial effects.  It is thought that any stimulatory effects of testosterone on 
the endometrium would occur via local aromatization to estrogen, but aromatase activity 
has not been detected in the endometrial environment.  Thus, testosterone should not 
have adverse uterine effects.  In an examination of endometrial biopsies from 
postmenopausal women before and after three months of treatment with oral testosterone 
alone, estradiol alone, or both provided direct evidence that testosterone did not have 
adverse uterine effects, whereas the women taking estrogen alone showed proliferative 
changes that increased by 50%.  Combined treatment resulted in a non-significant 
increase to 28%, which suggested that testosterone might counteract estrogen-induced 
proliferation.  These findings are similar to the results from the APHRODITE study, 
where treatment with testosterone did not result in any adverse endometrial assessed over 
12 months by trans-vaginal ultrasound and endometrial biopsy (Davis & Braunstein, 
2012).  Additionally, there were no cases of endometrial hyperplasia.   
Other safety concerns.  No trials to date of transdermal testosterone have reported 
liver toxicity nor has there been any hepatic dysfunction noted in trials of oral estrogen 
plus testosterone (Davis & Braunstein, 2012).  Additionally, there have been studies that 
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demonstrate that testosterone therapy decreased aggression, hostility, and anxiety in 
women and may even improve depression severity (R. Glaser & C. Dimitrakakis, 2013; 
Miller et al., 2009).  However, high doses of endogenous testosterone in female students 
were correlated with financial risk taking behavior and reduced interpersonal trust, 
particularly in highly trusting women (Davis & Braunstein, 2012). 
A safety study of LibiGel (testosterone gel).  Evaluation of the safety of hormonal 
preparation for the treatment of FSD is important to assess the benefit-to-risk profile of 
these drugs and has been strongly encouraged by the FDA.  The LibiGel Safety Study 
(BLISS) is the first large, long-term safety study of oophorectomized postmenopausal 
women aged 30-65 with HSDD receiving a dose of testosterone equal to ovarian 
production rate in younger women with normal menstrual cycles.  The study was 
enriched by including participants with an elevated CV risk (White et al., 2012).   
LibiGel, a low-dose testosterone gel, is under development for the treatment of 
HSDD (White et al., 2012).  To evaluate the long-term effects of LibiGel on risk for CV 
events, breast cancer, and general safety, a long-term randomized placebo controlled 
parallel group clinical study using a novel adaptive design to optimize sample size and 
power is currently being conducted with applications of 0.22 grams/day.  The primary 
endpoint of the BLISS study is a composite of CV events including death, nonfatal 
myocardial infarction, nonfatal stroke, coronary vascularization, hospitalized unstable 
angina, and venous thrombotic events.  Breast cancer is a co-primary endpoint.   
The active treatment phase of the study is longer than former studies and consists 
of 60 months of drug exposure.  The study had enrolled more than 2500 postmenopausal 
women with more than 2,200 women-years of exposure accrued.  Following four 
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unblended safety reviews by an independent data monitoring committee, the composite 
adjudicated cardiovascular event was 0.65% and breast cancer rate was 0.32%.  The 
conclusions thus far in this ongoing study conclude that low event rates in women at the 
higher end of the cardiovascular risk continuum for the intended treatment population 
support the lack of cardiovascular and breast cancer risk of testosterone (Davis & 
Braunstein, 2012). 
 Intra and Vulvovaginal testosterone.   There is thought to be a greater incidence 
of vaginal atrophy in women on AIs for breast cancer. The need for a safe and effective 
nonestrogen therapy for vaginal atrophy led to a study where 21 postmenopausal breast 
cancer patients on AI therapy with vaginal atrophy were treated with testosterone cream 
applied to the vaginal epithelium daily for 28 days. A 4-week course of vaginal 
testosterone was associated with improved signs and symptoms of vaginal atrophy related 
to aromatase therapy without increasing estradiol levels (Witherby et al., 2011).   
In another study, 75 postmenopausal women symptomatic for urogenital atrophy 
and sexual dysfunction were randomly divided into two study groups and one control 
group (Raghunandan, Agrawal, Dubey, Choudhury, & Jain, 2010).  The women in study 
group one received local estrogen cream, study group two received local estrogen and 
testosterone cream, and the control group received non-hormonal lubricant KY gel for 12 
weeks.  The Urogenital and Sexuality score, the Vaginal Health Index, and the Vaginal 
Maturation Index (VMI) were calculated at the beginning of therapy and 12 weeks later 
and served as the main outcome measures.  
After 12 weeks of therapy, there was a significant improvement in all the study 
parameters, which correlated well with the improvement in symptoms of urogenital 
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atrophy and sexual dysfunction in both study groups as compared with the control group.  
Improvement in sexuality score was greatest with combined estrogen-androgen therapy.  
There were no adverse effects noted and the therapies were well accepted without any 
compliance issue.  Local estrogen either alone or with an androgen such as testosterone 
were considered to be highly effective in relieving symptoms of urogenital atrophy and in 
improving sexual function in symptomatic postmenopausal women (Raghunandan et al., 
2010). 
In another study based on a literature review, it was concluded that oral, 
transdermal, or vaginal estrogen preparations are the most effective treatment options for 
vulvovaginal atrophy-related sexual dysfunction, though vaginal 
dehydroepiandrostenedione and vaginal testosterone are emerging as promising new 
therapies; however, it has been concluded that further studies are warranted to confirm 
efficacy and safety (Tan, Bradshaw, & Carr, 2012). 
Testosterone, the controversy.  It has been suggested that to prepare the market 
for a testosterone patch, HSDD was established by the medical and pharmaceutical 
industry in 2004 to sell product by medicalizing female sexuality.  Some researchers feel 
that the efficacy and safety concerns over administration of testosterone for this disorder 
have been trivialized and the potentially modest benefits have been overblown.  For 
example, the results of a 24-week randomized controlled trials of testosterone trials 
showed the testosterone patch increased the amount of satisfying sexual activity for 
women by around two episodes a month compared with the baseline which amounted to 
one extra episode compared with the placebo response.  These trials made some 
researchers question if the women enrolled were even dysfunctional being that the 
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amount of sexual episodes described were considered to be average in long term 
relationships (Moynihan, 2005).   
It has also been noted in the literature that many of the experts involved in testing 
the patch and in advocating for its approval had financial conflicts of interest.  An 
example given by Moynihan (2005) was that at least two of the senior academic 
investigators who tested the patch also ran private for-profit research companies that 
contracted with Proctor and Gamble to help carry out the clinical trials.  Of note, it was 
Proctor and Gamble who attempted to market a testosterone patch to women who became 
menopausal after ovarian surgery and reportedly suffered from HSDD.  Further, Harvard 
University Professor, Jan Shifren, a strong advocate of the testosterone patch had 
presented at medical events funded by unrestricted educational grants from Proctor and 
Gamble,  and that she was a paid member of the company’s advisory board (Moynihan, 
2005).  Shifren rejected the notion that the testosterone patch only showed modest 
increases in sexual activity and proposed that the way a woman feels about their desire 
problems and related distress are the key issues.   
Critics of testosterone for HSDD noted that the decrease in distress over placebo 
was only six or seven points on a 100 scale which raised serious questions about the 
meaningfulness of the purported benefits.  Though the FDA advisors voted to accept the 
patch benefits as clinically meaningful, they unanimously rejected the  testosterone patch 
company’s data as inadequate to assess long term safety, and unanimously recommended 
the agency not to improve the drug (Moynihan, 2005).  It was concluded that:  
The pharmaceutical industry’s strong commercial interest in this area may 
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ultimately bring benefits to women, through the development of safe and effective 
medicines, and through an increased understanding of female sexuality.  Yet, if 
those desirable benefits are to be achieved, we might have to start relying a little 
less on marketing and promotional campaigns about new diseases, dressed up in 
science and education.  (Moynihan, 2005, p. 194). 
Conclusion.  Early studies established that testosterone therapy improved sexual 
desire and activity in both naturally and surgically induced menopausal women.  Adverse 
side effects were primarily noted to be dose-dependent and androgenic in nature. 
Research was then conducted to explore a more efficacious administration route. 
Transdermal delivery of testosterone was discovered to have has advantages in that this 
delivery route avoided first pass hepatic metabolism and delivered a more consistent 
physiologic dose.  Many studies have shown that physiologic doses of approximately 300 
mcg/day are both efficacious at treating HSDD and have a low side effect profile (R. 
Glaser & C. Dimitrakakis, 2013; Nappi, 2015b).  Studies have shown that transdermal 
testosterone is considered safe for short-term application and may even have a cardio-
protective effect and reduce the likelihood of estrogen-dependent breast cancer.  
Nevertheless, there remains a controversy surrounding the application of 
testosterone for HSDD, primarily based over concerns that experts involved in testing the 
patch and advocating for its’ approval had financial conflicts of interest.  Some 
researchers have purported that the safety and efficacy have been trivialized, while its 
benefits have been overblown; however, the literature backing these claims pales in 
comparison to the large body of work that demonstrate the effectiveness and safety of 
physiologic doses of testosterone for hypoactive sexual desire and/or low libido.  
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Further, the timeline of events which came to be called the “Campaign for a New 
View of Women’s Sexual Problems” that in part challenged the pharmaceutical 
industry’s “aggressive interest in sex” and FSD “disease mongering” have been 
overshadowed by the Endocrine Society’s stance on the matter, after a panel of experts 
critically reviewed the research and suggested its use in targeted situations for HSDD 
(Tiefer, 2006).   
Primary Care and HSDD 
 
Abdolrasulina et al. (2010) asserted that 40% of women report female sexual 
problems, particularly sexual desire disorders and that there are numerous practical, 
professional, and personal barriers to the evaluation, diagnosis, and management by 
treating healthcare providers.  Additionally, sexual complaints usually arise in the context 
of other physical, psychological, and relationship issues (Parish, 2009).   
 Though sexual dysfunction is common in women and is associated with distress 
and burden as noted in key findings from large population-based studies, it remains 
underdiagnosed and undertreated (Nappi et al., 2010).  In part, this may be due to a 
patient’s reluctance to discuss it with their provider even when specifically asked about it.  
It is estimated that only 18% of women with sexual concerns will spontaneously 
volunteer information about sexual dysfunction with their healthcare provider (Wright & 
O'Connor, 2015). 
It is the duty of healthcare providers to inquire about their female patient’s 
sexuality because sexuality may impact the quality of the patient’s life or be a quality of 
life indicator (Zakhari, 2009).  Engaging in conversation about sexuality with the 
menopausal patient may be difficult due to the many barriers, prohibitive factors, and 
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misconceptions healthcare providers have regarding menopausal sexuality, including the 
idea that sexual problems are a normal part of aging and long relationships, and therefore, 
do not deserve specific treatments (Abdolrasulnia et al., 2010; Nappi et al., 2010).  
Discussions with patients about menopause-related HSDD may be inhibited by medical 
literature that questions whether HSDD is a medical condition warranting intervention 
with pharmacological treatment (Meixel et al., 2015; Tiefer, 2006). 
Additionally, the multitude of determinants of sexual desire across the life cycle, 
and the difficulties in establishing the level of discrepancy between expected and current 
desire in a specific relational context bring about the idea that HSDD is a condition 
difficult to treat.  Moreover, the healthcare providers personal experiences and cultural 
norms may modulate the inquiry into female sexuality and FSD, especially in menopause 
(Nappi et al., 2010). 
Studies related to practice patterns, perceptions, and barriers to the 
diagnosis and management of FSD.  To identify practice patterns, perceptions, and 
barriers to the diagnosis and management of female sexual problems among US 
practicing primary care physicians and obstetricians/gynecologists, a random sample was 
sent a case vignette survey by e-mail and fax to study the frequency and variability in 
diagnostic tests ordered and treatment recommendations provided for the patient with 
HSDD (Abdolrasulnia et al., 2010).  A total of 505 responses were analyzed (8.8% 
response rate).   
Of the respondents, 21% of OB/GYNs and 38% of PCPs stated they were not at 
all confident in treating HSDD.  The majority of physician respondents ordered a thyroid 
panel to assess diminished desire and recommended counseling and stress reduction 
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therapies to the female patient with sexual complaints.  Results of the study identified 
time constraints, the perceived lack of effective therapies, perceptions regarding patient-
physician gender discordance, years in practice, number of patient seen per week, and 
perceptions regarding continuing medical education and practice experience as 
significant an independent predictor of confidence in treating HSDD patients.  The 
conclusions were that discussion of sexual health is difficult and that there are predictors 
of confidence in treating patients with decreased desire.  Both PCPs and OB/GYNs rated 
the perceived lack of effective therapies as a significant challenge to initiating dialogue 
with patients about sexual problems.  Time constraints were also considered to be a 
moderate barrier to both groups.  Both groups perceived gender differences as a 
significant barrier to initiating dialogue as well (Abdolrasulnia et al., 2010).   
In another large population-based sample of 1,154 practicing OB/GYNs (53% 
male; mean age 48 years) was surveyed regarding their practices of communication with 
patients about sexuality and to examine the individual and practice-level correlates of 
such communication.  The survey response rate was 65.6%.  Sixty-three percent of 
OB/GYNS reported routinely assessing patient’s sexual activities and 40% routinely 
asked about sexual problems.  Fewer asked about sexual satisfaction (only 28.5 %) or 
pleasure with sexual activity (13%).  A quarter of OB/GYNs practicing reported that they 
had expressed disapproval of patient’s sexual practices.  The conclusions of the study 
were that the majority of US OB/GYNs reported routinely asking patients about their 
sexual activities but most other areas of patient’s sexuality are not routinely discussed 
(Sobecki et al., 2012). 
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In one small pilot study, all residents and faculty in an academic primary care 
clinic were invited to participate in a web-based survey regarding HSDD that included a 
10-item questionnaire regarding HSDD.  In total, 53 of the 155 physicians responded 
(34% response rate).  Of the respondents, 90% reported little confidence in making the 
diagnosis of HSDD, 90% of the physicians had not screened a patient for HSDD, and 
98% of the physicians had not prescribed medication for patients for HSDD.  The results 
indicated that there was an opportunity to improve patient care and life satisfaction by 
offering physicians training on diagnosis and management of HSDD (Harsh et al., 2008). 
An internet-based survey was constructed to evaluate third and fourth year 
residents in American Council for Graduate Medical Education-approved OB/GYN 
programs.  Residents were asked about familiarity, knowledge, and confidence in treating 
various aspects of female sexual function and dysfunction.  Two hundred and thirty-four 
residents responded.  Only 19.6% reported often or always screening women for sexual 
function problems; most had very little knowledge in administering or interpreting 
questionnaires.  Many felt confident about obtaining a complete sexual history; however, 
only a minority of 18.4% had managed women with low desire.  The conclusions were 
that despite CREOG requirements for OB/GYN training in female sexuality, most 
residents felt ill equipped to address these problems (Pancholy et al., 2011).   
Biological and sociocultural differences between men and women may play an 
important role in medical treatment (Loikas et al., 2015).  In one study, PCPs stated they 
had little knowledge of sex and gender differences in drug treatment, but gave multiple 
examples of how the patient’s sex affects the choice of treatment (Loikas et al., 2015).  
This indirectly correlates with the aforementioned study of OB/GYN practices where 
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female OB/GYNs were significantly more likely than males to routinely ask patients 
about sexual activity. 
Primary care and testosterone for HSDD.  In one study, interviews and an 
opinion poll of gynecologists and family medicine physicians were conducted to identify 
the current prescribing pattern of off-label testosterone use in treating HSDD. The 
Intercontinental Marketing Services (IMS) prescription review showed that two million 
testosterone prescriptions were written for women in 2006 and 2007, many of which were 
compounded testosterone.  Based on a summary of the physicians’ survey on average 
patients of all ages, but particularly menopausal women, have at least moderate 
awareness of HSDD.  More than 80% of physicians believe that there is a need or great 
need for a FDA approved HSDD treatment and 90% of physicians surveyed would 
prescribe an approved HSDD product over currently prescribed therapy (Snabes & 
Simes, 2009).  
Summary  
Researchers have concluded that the healthcare provider needs to be aware of all 
the potential influences lending to HSDD, including their own biases and perceptions 
including the underestimation of the prevalence of sexual dysfunction or its impact on 
quality of life (Frank et al., 2008).  Discomfort with the topic, difficulty with the 
diagnosis, lack of provider confidence, inadequate training, limited treatment options, and 
insufficient clinical time with the patient to discuss in depth sexual histories all contribute 
to inadequate management of female sexual problems, namely menopause related HSDD 
(Frank et al., 2008; Wright & O'Connor, 2015). 
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It is suggested that treatment for menopause-related HSDD should encompass a 
holistic multidisciplinary approach including counseling, psychosexual therapy, and 
appropriate evidenced-based pharmacotherapy.  The approach to management should 
address any factors that might be amenable to intervention, whether or not they constitute 
the primary cause of the complaint of loss of libido (Parish, 2009).  With improved 
access to medical care and nutrition, the average life expectancy for women is increasing 
along with an interest in maintaining sexual function.  
Though testosterone has been utilized for decades for various disorders and 
conditions and has demonstrated its safety and efficacy, it is still an underutilized 
treatment for low libido and diminished sexual desire in the naturally occurring 
menopausal female.  One researcher summarized his life-long work with testosterone by 
stating the following: 
Today, there is a dominant narrative that the benefits of TTh [testosterone 
therapy] are unproven, the risks are substantial, and TTh is abused and overused 
because of physicians yielding to unwarranted demand by misguided patients who 
are unwilling to accept normal aging. Although there is no evidence to support 
this position, and considerable evidence to the contrary, this narrative has trumped 
the facts within the public media.  The impact of this vilification of TTh has been 
substantial, discouraging symptomatic patients from accepting a potentially 
beneficial treatment, and generating suspicion of physicians offering TTh by their 
colleagues, for questionable medical practices.  This is unfair to patients and 
physicians alike (Morgentaler, 2016).  
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HSDD in naturally occurring menopause is considered by some to be 
medicalization of a normal state where providers of healthcare are persuaded by the 
pharmaceutical industry to meet an unmet need with pharmaceutical interventions, such 
as testosterone, in order to sell a product. The average woman making the transition into 
menopause can expect to live for at least 25 years and with the increased expectations for 
a longer and healthier life, women are more interested in maintaining sexual function 
(Thornton et al., 2015).  If sexuality is a quality of life indicator and primary care 
providers and providers of gynecologic healthcare are encouraged to treat patients 
holistically, then help with maintaining a patient’s sexuality (if it is important to that 
particular patient) falls within their scope of practice. 
Gaps in the Medical Literature  
To gain a deeper understanding of why testosterone remains underutilized by the 
medical community in the primary care setting for low libido and diminished sexual 
desire in menopause despite its proven efficacy and safety, gaps in the medical literature 
were critically analyzed.  
First, it is unclear in the medical literature if primary care providers and providers 
of gynecological healthcare consider low libido and diminished sexual desire in the 
naturally occurring menopausal female to be a medical condition or disorder, a natural 
part of aging, or both and whether or not their opinion on the matter would impact 
evaluation, diagnosis, and/or the choice of treatment for this problem.  
Secondly, while there are ample studies in the literature that demonstrate low 
libido and diminished sexual desire are the most common female sexual complaints and 
that these problems cause considerable distress and interpersonal difficulties, especially 
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in menopause, there remains a paucity in the literature regarding provider’s perceptions, 
knowledge, and experiences regarding pharmaceutical treatment for these complaints. 
Furthermore, there is paucity of literature about provider’s knowledge of and experience 
with testosterone, specifically for HSDD, in naturally occurring menopausal women.  
Additionally, there has been very little discussion in literature that questions whether 
estrogen unopposed by testosterone may be a cause or contributing factor in the increased 
risk of breast and endometrial cancer. 
Lastly, while the literature speaks to closing the gender gap in sexual medicine, it 
does not specifically challenge the medical establishments as to why testosterone cannot 
be prescribed or suggested for menopausal women who are not in any particular distress 
and/or not having interpersonal difficulties seeking to maintain their sexual function and 
sexual satisfaction and who are “otherwise healthy.” 
Chapter 3: Methods 
Sample, Subjects, and Setting 
As this research involves human subjects, it underwent a review and approval 
from the University of Vermont Institutional Review Board (IRB) prior to initiation of 
the study.  The IRB determined the study to be exempt (See Appendix A).  Respondents 
in this study were a convenience sample of primary care providers (PCPs) and 
gynecologic health care providers.  The inclusion criteria included those PCPs who are 
currently practicing or have practiced in the last two years in the primary care setting for 
the care of menopausal women primarily in the professional role of physician, nurse 
practitioner or physician assistant.  Recruitment for this study was accomplished through 
listservs of the following Vermont-based professional organizations: the Vermont Nurse 
 59 
 
Practitioners Association (VNPA), the Vermont Academy of Family Physicians 
(VTAFP), and the Physician Assistant Academy of Vermont (PAAV).  
The inclusion criterion was specified in the electronic mailings along with 
notification that participation in the survey will be considered consent.  Participation in 
the survey was voluntary.  The respondents remained anonymous throughout the survey 
process and thereafter.   
Design  
 
The study design was a descriptive cross-sectional online LimeSurvey.  The 
LimeSurvey was sent out electronically to listserv e-mails of potentially eligible 
respondents on a secure server through the University of Vermont.   
At the beginning of the survey, the respondents were informed that participation 
in the study was both voluntary and anonymous.  Anonymity remained throughout the 
survey process and thereafter.  Respondents had to meet inclusion criteria, which were 
established by answering a single question at the beginning of the survey: Are you a 
primary care provider or provider, a gynecologic health care provider, or a specialty 
provider who is currently practicing or who has practiced within the last two years with a 
patient population that includes naturally occurring menopausal females?  If the 
respondents met the inclusion criteria, they were asked to proceed with the survey 
questionnaire.  Respondents were asked to answer the questions as accurately as possible. 
After the initial invitation to participant in the online LimeSurvey was submitted 
on October 7, 2016 it was available to the respondents for completion for three weeks 
afterwards by the end date of October 28, 2016. 




The instrument of study was a cross-sectional online survey of PCPs and 
providers of gynecologic healthcare in the state of Vermont.  Data collection was through 
LimeSurvey, an online server-based software that collected responses, generated 
statistics, and exported the resulting data to other applications.  Content validity of the 
online survey was established through a comprehensive literature review as well as a 
review by a panel of experts in the field of women’s health.  Reliability was not 
established. 
Data Analysis  
 
Following the conclusion of the descriptive cross-sectional online survey, the data 
was exported to a Microsoft Excel Spreadsheet through the LimeSurvey software.  The 
data was analyzed using descriptive statistics and was critically examined.   
Chapter 4: Results 
Section One: Respondent Inclusion Criteria.   
Forty-seven respondents participated in the study.  Forty-six respondents met the 
respondent inclusion criteria (N=46) as described in Chapter 3.  
Section Two: Respondent Demographic Information.    
Twenty-two respondents (48%) were physicians in primary care (including one 
DO, an osteopathic physician, one in family medicine, and one in family practice in a 
reproductive health setting), one was a MD specialist (OB-GYN) (2%), 17 respondents 
(37%) were NP primary care providers, one respondent was a NP specialist in women’s 
health (2%), two respondents were certified nurse midwives (CNMs) (4%), and two 
respondents were in PA primary care (4%) and two in PA specialty care (4%).   Fifteen 
respondents (33%) were in practice less than five years.  Five respondents (11%) were in 
 61 
 
practice five to ten years.  Eleven respondents (24%) were in practice ten to 20 years and 
15 respondents (33%) were in practice for greater than 20 years.  Forty respondents 
(87%) were female and 6 respondents (13%) were male.  
Figure 2. Respondent Professional Title 
 
Section Three: Menopause, Sexuality, and Evaluation of Female Sexual Dysfunction 
(FSD).    
Forty-five respondents (98%) believe that sexuality and sexual satisfaction should 
be quality of life indicators and perceived that maintaining sexual function is important to 
the naturally occurring menopausal women that they serve.  One respondent (2%) did not 
answer either question above.  Twenty-five respondents (54%) consistently screen 
naturally occurring menopausal women for sexual dysfunction at each comprehensive 
health care visit regardless of age, health status, or life circumstances, while 20 (43%) do 
not.  One respondent did not answer (2%).   
MD Primary Care, 48%
NP Primary Care, 37 %
MD Specialist, 2%
PA Primary Care, 4%
PA Specialist, , 4% NP Specialist, 2% CNM, 4%
Respondent  Professional Title
MD Primary Care NP Primary Care MD SpecialistPA Primary Care PA Specialist NP SpecialistCNM
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Section Four: Low Libido and Diminished Sexual Desire in Naturally Occurring 
Menopause.    
Thirty-three respondents (72%) consider low libido and/or diminished sexual 
desire in naturally occurring menopause to be both a medical condition or disorder and a 
natural part of aging, while 6 respondents (13%) consider it to be a natural part of aging, 
and 6 respondents (13%) consider it to be a medical disorder (Figure 3).  One respondent 
did not answer (2%).  Twenty-seven respondents (59%) have prescribed a pharmaceutical 
treatment for naturally occurring menopausal women whose chief compliant was low 
libido and/or diminished sexual desire, while 18 (39%) have not.  One respondent did not 
answer (2%).  Twenty-nine respondents’ opinion (63%) was that naturally occurring 
menopausal woman have reported feeling distressed and/or having interpersonal 
difficulties related to sexual dysfunction in order to receive pharmaceutical treatment for 
low libido or diminished sexual desire, while 16 (35%) did not.  One respondent did not 
answer (2%).  Forty-three respondents (93%) would prescribe a pharmaceutical treatment 
for a naturally occurring menopausal woman who was otherwise healthy and seeking to 
maintain her sexual function and enhance sexual satisfaction as long as there were no 
contraindications and two (4%) would not.  One respondent did not answer (2%).  





Section Five: Testosterone and Hyposexual Desire Disorder (HSDD).  
 The respondents were asked to indicate with confidence whether each of the 
following 11 statements about testosterone were true or false.  If the respondent could not 
answer with confidence, he or she was asked to choose “unable to answer”.  Not 
answering was also an option.  This section was designed so that answers chosen to be 
true reflected a respondent’s accurate knowledge of the statement, while answers chosen 
to be false represented inaccurate knowledge on behalf on of the respondent.  There were 
a total of 506 truths (most knowledgeable) in section five based on 11 statements and 46 
respondents in the study.  
Testosterone is not approved by the FDA for HSDD.  Nineteen respondents 
(41%) thought this statement was true while seven (15%) thought this statement was 
false.  Eighteen respondents (39%) were unable to answer with confidence and two 
respondents (4%) did not answer.  Currently, testosterone is not approved by the FDA for 




Etiology of Low Libido and Diminished Sexual 
Desire in Menopause
Both a medical condition/disorder and a natural part of agingA natural part of agingA medical disorderNo answer
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Sufficient long-term safety and efficacy data is lacking for treatment of 
HSDD with transdermal testosterone.  Twenty-six respondents (57%) thought this 
statement was true while two (4%) thought this statement was false.  Fifteen respondents 
(33%) were unable to answer with confidence and three (7%) did not answer.  According 
to the FDA and the Endocrine Society, there is insufficient long-term safety data when 
testosterone is used for this purpose.   
According to most studies, testosterone prescribed for HSDD has not been 
shown to increase the risk or incidence of breast cancer in women.  Eighteen 
respondents (39%) thought that this statement was true and one (2%) thought this 
statement was false.  Twenty-four respondents (52%) were unable to answer with 
confidence and three respondents (7%) did not answer.  Phase three clinical trials have 
shown that testosterone does not increase the risk or incidence of breast cancer when used 
for this purpose.  
Physiologic doses of transdermal testosterone for women do not increase the 
risk of heart disease and are not associated with adverse changes to the lipid profile.  
Eleven respondents (24%) thought this statement was true while ten (22%) did not. 
Twenty-three respondents (50%) were unable to answer with confidence and two (4%) 
did not answer the question.  Phase three clinical trials have shown that testosterone does 
not increase the risk or incidence of heart disease and/or changes in the lipid profile when 
used for this purpose.  
According to most studies, testosterone prescribed for HSDD has not been 
shown to cause endometrial hyperplasia and does not lead to endometrial cancer in 
women.  Fifteen respondents (33%) thought that this statement was true and one (2%) 
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thought this statement was false.  Twenty-seven respondents (59%) were unable to 
answer the statement with confidence and three (7%) did not answer the question.  
Studies have shown that testosterone does not cause endometrial hyperplasia and/or 
endometrial cancer when used for this purpose.  
The most common adverse events/side effects reported with use of 
transdermal testosterone for HSDD are androgenic in nature and dose dependent. 
Twenty-five respondents (54%) thought this statement was true and no one thought the 
statement was false.  Nineteen respondents (41%) were unable to answer with confidence 
and two respondents (4%) did not answer. Along with adhesive site reactions from 
transdermal patches, the most common side effects reported are androgenic and dose 
dependent.  
Testosterone is the most abundant biologically active female sex hormone in 
women throughout their lifespan.  Ten respondents (22%) thought this statement was 
true while 12 (26%) thought this statement was false.  Twenty-two respondents (48%) 
were unable to answer with confidence and two (4%) did not answer. 
Testosterone is FDA approved for treatment of metastatic breast cancer in 
menopausal women and hormone-responsive breast cancer in premenopausal 
women post- oophorectomy.  Three respondents (7%) thought the statement was true 
and 11 (24%) thought this statement was false.  Thirty respondents (65%) were unable to 
answer with confidence and two respondents (4%) did not answer.  Testosterone is 
approved for metastatic breast cancer and in premenopausal women post-oophorectomy 
especially in cases with metastasis to the bone.  
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Intra and vulvovaginal testosterone improves symptoms of urogenital 
atrophy and sexual dysfunction.  Ten respondents (22%) thought that this statement 
was true and nine (20%) thought this statement was false.  Twenty-five respondents 
(54%) were unable to answer with confidence and two (4%) did not answer.  In recent 
studies, testosterone had been shown to improve urogenital atrophy and sexual 
dysfunction in both women taking aromatase inhibitors and in naturally occurring 
menopause with age related vaginal complaints.  
Testosterone therapy in menopausal women increases the frequency of 
satisfying sexual activity, sexual desire, and orgasmic response.  Sixteen respondents 
(35%) thought that this statement was true and four (9%) thought this statement was 
false.  Twenty-four respondents (52%) were unable to answer with confidence and two 
(4%) did not answer.  Many studies have proven testosterone’s ability to increase the 
frequency of satisfying sexual activity, sexual desire, and orgasmic response in woman 
with complaints of low libido and/or diminished desire. 
Currently, testosterone therapy for HSDD is contraindicated in women with 
breast, uterine, and cardiovascular disease.   Fifteen respondents (32%) thought this 
statement was true and one (2%) thought this statement was false.  Twenty-eight 
respondents (61%) were unable to answer with confidence and two (4%) did not answer. 
According to the Endocrine Society’s CPGs, testosterone therapy remains contraindicated 
in women with breast, uterine, and cardiovascular disease.  
Overall, 168 responses (33%) were chosen to be true, 58 responses (12%) were 
chosen to be false, 255 responses (50%) were unable to be answered with confidence, and 
25 responses (5%) were not answered.  The average/mean number of truths chosen per 
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testosterone prescriber was 6.07, while the average/mean number of truths chosen for 
respondents who have never prescribed testosterone was 2.87 (Figure 5).  
Figure 4. Testosterone Knowledge 
 
 
Figure 5. Truths Chosen Between Prescribers and Non-Prescribers of Testosterone 
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Section Six: Hyposexual Desire Disorder (HSDD) and Clinical practice Guidelines.  
Thirty-one respondents (67%) have never prescribed testosterone for naturally 
occurring menopausal women who sought help for low libido and/or diminished sexual 
desire and 13 (28%) have prescribed testosterone for this purpose.  Forty-two respondents 
(91%) had not reviewed the updated 2014 clinical practice guidelines (CPGs) set forth by 
the Endocrine Society regarding androgen/testosterone therapy in women with 
hyposexual desire disorder while two respondents (4%) have reviewed the guidelines. 
One respondent did not answer either question (2%).   
Additional Statistical Analysis.  
Of the 25 respondents who consistently screen menopausal women for sexual 
dysfunction eight respondents (32%) have prescribed testosterone.  Of the 20 respondents 
that do not consistently screen patients for sexual dysfunction, five respondents (25%) 
have prescribed testosterone.   
Chapter 5: Discussion 
Comments  
 Forty-five respondents (98%), predominately female, believe that sexuality and 
sexual satisfaction should be quality of life indicators and perceived that maintaining 
sexual function is important to the naturally occurring menopausal women that they serve 
regardless of professional title, years in practice, or gender.  Further, 43 respondents 
(94%) would prescribe a pharmaceutical treatment for a naturally occurring menopausal 
woman who was otherwise healthy and seeking to maintain her sexual function and 
enhance sexual satisfaction as long as there were no contraindications.  Yet, only 25 
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respondents (54%) consistently screen naturally occurring menopausal women for sexual 
dysfunction at each comprehensive health care visit. 
 Interestingly, though the vast majority of respondents acknowledged that 
menopausal sexuality and subsequently sexual satisfaction and function were important 
and that they would prescribe a pharmaceutical treatment for healthy women for these 
purposes, 29 respondents (63%) answered yes to the statement that naturally occurring 
menopausal women have to report feeling distressed and/or having interpersonal 
difficulties related to sexual dysfunction in order to receive pharmaceutical treatment for 
low libido and/or diminished sexual desire.  Hence, the respondent’s opinions and 
practices were contradictory in this section.  This may reflect the fact that there is not yet 
a clear stance in the medical literature on what or to what degree constitutes “distress” in 
relation to a diagnosis of HSDD, and a definition of distress and interpersonal difficulty 
was not provided to the respondent prior to the questions in this section.  Furthermore, 
the contradictory responses may be related to the confusion and debate over whether low 
sex drive and low sexual desire in menopause is a medical condition or disorder, a natural 
part of aging, or both; thirty respondents (65%) consider low libido and/or diminished 
sexual desire in naturally occurring menopause to be both a medical condition or disorder 
and a natural part of aging, while 17 respondents (36%) consider it to be a natural part of 
aging, and eight respondents (17%) consider it to be a medical disorder.  
Nevertheless, provider confidence regarding knowledge about research regarding 
testosterone, a safe and efficacious treatment for HSDD, is lacking.  Only 33% of the 11 
statements about testosterone were answered accurately, while 12% were answered 
inaccurately.  Approximately half of the respondents (50%) could not answer the 11 
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statements that tested their knowledge of testosterone with confidence.  The majority of 
the respondents (67%) had never prescribed testosterone for naturally occurring 
menopausal women who sought help for low libido and/or diminished sexual desire, 
which may reflect the lack of provider confidence and knowledge regarding testosterone.  
The results showed that prescribers of testosterone were more knowledgeable about 
testosterone used for this purpose than non-prescribers.  This may indicate that the more 
knowledge a provider has about testosterone for HSDD, the more likely they are to 
prescribe testosterone for this purpose than not.  Nearly all respondents (91%) had not 
reviewed the updated 2014 CPGs set forth by the Endocrine Society regarding 
androgen/testosterone therapy in women with HSDD.  Though this is not statistically 
significant, the two respondents that had reviewed the Endocrine Society’s CPGs 
regarding androgen therapy had prescribed testosterone for menopausal patients 
complaining of low libido and/or desire.   
Conclusions  
Providers believe that sexuality and sexual satisfaction are quality of life 
indicators and perceived that maintaining sexual function is important to the naturally 
occurring menopausal women that they serve, and the majority of providers would 
prescribe a pharmaceutical treatment for menopausal women seeking to maintain their 
sexual function, enhance sexual satisfaction, and/or treat symptoms of HSDD as long as 
there were no contraindications.  However, testosterone is a proven treatment for women 
with complaints of low libido and/or diminished sexual desire, which was reportedly 
underutilized for this purpose.  This may be related to inconsistent screening for FSD in 
menopause at each comprehensive visit and lack of provider knowledge about 
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testosterone (including safety and efficacy) used for this purpose.  Further, providers are 
divided on whether low libido and/or diminished sexual desire in naturally occurring 
menopause is a medical condition or disorder or a natural part of aging.  It is unclear if 
this impacts evaluation and treatment.  
 
Limitations of the Study 
  
 The primary limitation of the study was that the respondent sample size was 
small.  Generalizability was lacking because participation was from Vermont based 
organizations only.  Further, OB GYNs were not well represented in this study.  There 
was an insufficient amount of time to carry out the survey in order to obtain as many 
respondents as possible and there were no reminders to participate in the study prior to 
the deadline.  The instrument design was inflexible in that most of the questions and 
answer choices were in a yes or no format. Therefore, the questions that may have been 
considered controversial or complicated may not have been answered with accuracy and 
may have been better-represented using alternative data gathering methods such as 
personal interviews and/or Likert scales.  The study instrument tool was not 
psychometrically tested and while content validity was established, reliability was not. As 
already mentioned, the meaning of distress was not clearly elucidated in the study, which 
may have impacted the results. 
Suggestions for Further Research  
 
 For the PCPs and gynecological healthcare providers who prescribe testosterone 
for low libido and/or diminished sexual desire, research is needed to assess provider 
perceptions about the efficacy of the treatment as well as their experiences with being a 
testosterone prescriber for this purpose.  More research is needed to explore 
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testosterone’s role in treating antidepressant induced sexual dysfunction in patients who 
cannot reduce or discontinue their psychotropic medication.  Qualitative research 
involving personal in depth interviews are necessitated that compare naturally occurring 
menopausal women’s sexual perceptions, feelings, and experiences before and after 
treatment with testosterone.  Additionally, studies are needed to explore the partner’s (of 
the patient prescribed testosterone for low libido and/or diminished desire) perceptions, 
feelings, and experiences. 
 
Suggestions for Primary Care Practice 
 
Primary care providers and providers of gynecological healthcare must screen 
menopausal woman for sexual concerns or complaints at every comprehensive visit 
regardless of age, life circumstances, or medical history with a brief FSD questionnaire 
(Figure 6).  For complaints of low libido and/or diminished sexual desire and/or for the 
diagnosis of HSDD, transdermal testosterone should be suggested in eligible patients.  
Furthermore, transdermal testosterone should be suggested for naturally occurring 
menopausal women who seek to maintain their sexual function and satisfaction in the 
primary care setting.  
Suggestions for the Endocrine Society Regarding CPGs for HSDD  
If distress is the hallmark for a diagnosis of HSDD, the Endocrine Society must 
first define distress in their CPGs for treatment of this disorder.  Most importantly, the 
Endocrine Society must delineate between menstruating women with and without 
androgen deficiency, surgically menopausal women, and women across the menopausal 
transition and thereafter in the treatment approach for HSDD with testosterone therapy 
including routes of administration and dosage.  Additionally, the Endocrine Society must 
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change the tone spoken of this “disorder.” To proclaim that testosterone should not be 
suggested to “otherwise healthy women” is misleading and clearly does not address the 
needs of menopausal women with naturally low androgen levels seeking to maintain their 
sexual function and satisfaction.  Lastly, the Endocrine Society must explain why 
testosterone administration is contraindicated in women with a history of breast cancer 
when it is approved by the FDA for metastatic breast cancer. 
Figure 6. Brief Sexual Symptom Checklist 
 
 
Figure 6. Hatzichristou, D., Rosen, R. C., Broderick, G., Clayton, A., Cuzin, B., 




Primary care providers and providers of gynecologic healthcare are in positions to 
advance sexual health for women in naturally occurring menopause.  To do so, leaders in 
 74 
 
this arena must help the individual, society, and the medical establishments relinquish 
stereotypes and embrace a new vision of menopause and sexuality.  Leaders can advance 
sexual health in menopause by embracing the attitude that though menopause signals the 
end of reproductive capacities, it does not necessarily end a woman’s interest in sexual 
activity or enjoyment.  In fact, menopause can be a vital new phase of life with 
continuation of healthy sexual expression if the patient is interested.  Primary care 
providers and provider of gynecological healthcare can focus on patient-provider 
communication and patient empowerment through shared knowledge, so that patients can 
make informed personal choices about their sexual health.  One way to advance sexual 
health for menopausal women is to screen for FSD at every comprehensive visit 
regardless of patient circumstances and to suggest transdermal testosterone for patients 
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Research Information Sheet  
 
Title of Study: Sex, Desire, and Menopause! 
Principal Investigator (PI): Kelly White, RN FNP student   
Faculty Sponsor: Professor Amy O’Meara, DrNP, WHNP, AGNP 
Funder: NA     
Introduction 
You are being invited to take part in this research study, because you may be a 
primary care or gynecological healthcare provider for menopausal women. Your 
participation is very important and will be greatly appreciated! This study is being 
conducted by Kelly White, RN FNP student and was developed as partial fulfillment 
of the requirements of the 2016 University of Vermont’s Master Science Degree 
Specializing in Nursing. 
Purpose  
This is a study of provider perceptions, knowledge, and practice of current practice 
guidelines for delivering health care to women experiencing hypoactive sexual desire 
and/or low libido in naturally occurring menopause with a focus on transdermal 
testosterone.  
Study Procedures and Consent 
If you decide to take part in the study, the survey can be found on the link/URL 
address provided in this e-mail located below and is on a secure server through the 
University of Vermont. This survey will only take approximately 5-10 minutes of 
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your time to complete.  Respondents can save partially finished surveys and return 
to them later. The survey will only be available through October 28th 2016. You 
may receive a reminder to take the survey. 
This survey is presented group by group in a multiple-choice and yes/no format. 
There are 25 questions divided into 6 groups. The first question is mandatory, 
because it involves respondent inclusion criteria. After the initial question, you will 
have the option to not answer any of the other questions in the survey. By 
participating in the survey, you are providing consent.   
Benefits and Risks 
As a participant in this research study, there may or may not be any direct benefit for 
you; however, information from this study may benefit other people now or in the 
future. We will do our best to protect the information we collect from you during this 
study. We will not collect any information that will identify you to further protect 
your confidentiality and avoid any potential risk for an accidental breach of 
confidentiality. If there is an accidental breach of confidentiality, you will be 
contacted and notified immediately.  
Costs and Compensation 
There will be no costs to you for participation in this research study. You will not be paid 
for taking part in this study.   
Confidentiality 
All information collected about you during the course of this study will be stored without 
any identifiers (anonymous).  No one will be able to match you to your answers. 
Anonymity will remain throughout the survey process and thereafter. The respondent 
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information data provided will be kept separate from the survey questions. No respondent 
identifying information will be given to the principle investigator conducting this study.  
Voluntary Participation/Withdrawal  
Taking part in this study is voluntary.  You are free to not answer any questions or 
withdraw at any time.  You may choose not to take part in this study, or if you decide to 
take part, you can change your mind later and withdraw from the study.  
Questions 
If you have any questions about this study or wish to enquire about the results of this 
study, please do not hesitate to contact: Kelly White, RN FNP student at (802) 299-7728 
(c) or (802) 672-2251 (h).  If you have questions or concerns about your rights as a 
research participant, then you may contact the University of Vermont’s Director of the 
Research Protections Office at (802) 656-5040.  Please keep a record of this contact 
information now. Thank you for your time and cooperation.  It is greatly appreciated! 
Participation 
Your participation is voluntary, and you may refuse to participate without penalty or 
discrimination at any time. Please print this information sheet for your records 
before continuing. 
The link is located at the following URL address: 
https://survey.uvm.edu/index.php/973468?lang=en 
Much appreciation and many thanks,  







Survey Introduction and Questions 
 
The following survey was developed as partial fulfillment of the requirements of the 
2016 University of Vermont’s Master of Science Degree Specializing in Nursing. 
Sex, Desire, and Menopause! 
                                                Introduction 
This is a study of provider perceptions, knowledge, and practice of current practice 
guidelines for delivering health care to women experiencing hypoactive sexual desire 
and/or low libido in naturally occurring menopause. 
Please take the time to ensure that your position is represented as accurately as possible. 
Your response is greatly appreciated and very important! Therefore, please take the time 
to ensure your position is represented as accurately as possible without the use of any 
references or materials. 
This survey will only take approximately 5-10 minutes of your time to complete. 
Only the first question is mandatory because it involves respondent inclusion criteria. 
You have the option to not answer any of the other questions in this survey. However, if 
possible, please complete the survey to the best of your ability and answer each question. 
There are a total of 24 questions in this survey divided into six groups. You can review 
your previous answers and make changes as needed prior to submitting the survey. 
Much appreciation and many thanks! 




Section One: Respondent Inclusion Criteria 
1) Are you a primary care provider or provider, a gynecologic health care provider, or a 
specialty provider who is currently practicing or who has practiced within the last two 
years with a patient population that includes naturally occurring menopausal females? If 
NO, please EXIT this survey now.  Thank you for your time. Yes or No 
 
Section Two: Respondent Demographic Information 
1) What is your professional title? Please note your practice specialty in the comment box 
provided and/or any other professional title not represented in this question.  (MD 
primary care, MD specialty care, PA primary care, PA specialty care, CNM, NP primary 
care, NP specialty care)  
2) How many years have you been in practice? <5, 5-10, 11-20, >20 
3) What is your gender identity? Male, Female, or Other 
 
Section Three: Menopause, Sexuality, and Evaluation of Female Sexual Dysfunction 
(FSD) 
1) In general, do you believe sexuality and sexual satisfaction should be quality of life 
indicators for naturally occurring menopausal women?  
2) In general, do you perceive that maintaining sexual function is important to the naturally 
occurring menopausal women that you serve? Yes or No 
3) In general, do you consistently screen naturally occurring menopausal women for sexual 
dysfunction at each comprehensive health care visit regardless of age, health status, or 




Section Four: Low Libido and Diminished Sexual Desire in Naturally Occurring 
Menopause 
1) Do you consider low libido and/or diminished sexual desire in naturally occurring 
menopausal women to be a medical condition or disorder, a natural part of aging, or 
both? Medical condition or disorder, A natural part of aging, Both a medical condition or 
disorder and a natural part of aging 
2) Have you ever prescribed a pharmaceutical treatment for naturally occurring menopausal 
women whose chief compliant was low libido and/or diminished sexual desire? Yes or 
No 
3) In your opinion, does the naturally occurring menopausal woman have to report feeling 
distressed and/or having interpersonal difficulties related to sexual dysfunction in order to 
receive pharmaceutical treatment for low libido or diminished sexual desire? Yes or No 
4) Would you prescribe a pharmaceutical treatment for a naturally occurring menopausal 
woman who was otherwise healthy and seeking to maintain her sexual function and 
enhance sexual satisfaction as long as there were no contraindications? Yes or No 
 
Section Five: Testosterone and Hyposexual Desire Disorder (HSDD) 
Please indicate with confidence whether you consider each of the following statements to 
be true or false. Please do not guess at the answer. Your answers should reflect both your 
knowledge and perceptions. If you cannot answer with confidence, please mark that you 




1. Testosterone is not approved by the FDA for HSDD.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
2. Sufficient long-term safety and efficacy data is lacking for treatment of 
HSDD with transdermal testosterone.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
3. According to most studies, testosterone prescribed for HSDD has not been 
shown to increase the risk or incidence of breast cancer in women.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
4. Physiologic doses of transdermal testosterone for women do not increase the 
risk of heart disease and are not associated with adverse changes to the lipid 
profile.  
Please choose only one of the following: 
x True  
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x False  
x Unable to Answer  
5. According to most studies, testosterone prescribed for HSDD has not been 
shown to cause endometrial hyperplasia and does not lead to endometrial 
cancer in women.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
6. The most common adverse events/side effects reported with use of 
transdermal testosterone for HSDD are androgenic in nature and dose 
dependent.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
7. Testosterone is the most abundant biologically active female sex hormone in 
women throughout their lifespan.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
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8. Testosterone is FDA approved for treatment of metastatic breast cancer in 
menopausal women and hormone-responsive breast cancer in 
premenopausal women post-oophorectomy.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
9. Intra and vulvovaginal testosterone improves symptoms of urogenital 
atrophy and sexual dysfunction.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
10. Testosterone therapy in menopausal women increases the frequency of 
satisfying sexual activity, sexual desire, and orgasmic response.  
Please choose only one of the following: 
x True  
x False  
x Unable to Answer  
11. Currently, testosterone therapy for HSDD is contraindicated in women with 
breast, uterine, and cardiovascular disease.  
Please choose only one of the following: 
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x True  
x False  
x Unable to Answer  
Section Six: Hyposexual Desire Disorder (HSDD) and Clinical practice Guidelines 
1) Have you ever prescribed testosterone for naturally occurring menopausal woman who 
sought help for low libido and/or diminished sexual desire? Yes or No 
2) Have you reviewed the updated 2014 clinical practice guidelines (CPGs) set forth by the 
Endocrine Society regarding androgen/testosterone therapy in women with hyposexual 

















“It’s okay to talk about birth, okay - then menstruation. I first started my advocacy 
for women’s health in the field of reproductive freedom, and the next stage would be 
bringing menopause out of the closet.” Cybill Shepherd 
  
